Drug Consumption in Current Year (Period 201901

Home , Amorolfine, Andexanet alfa, ATC code A07, ATC code A16, ATC code B03, ATC code G02

Page 1 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

A ALIMENTARY TRACT AND METABOLISM 323,80 3 4 321 589 7 4 A01 STOMATOLOGICAL PREPARATIONS 14,28 4 12 2 090 9 8 A01A STOMATOLOGICAL PREPARATIONS 14,28 4 12 2 090 9 8 A01AA Caries prophylactic agents 11,90 3 14 663 8 9 A01AA01 sodium fluoride 11,90 3 14 610 8 10 A01AA03 olaflur - - - 53 1 -2 A01AB Antiinfectives for local oral treatment 2,36 8 2 1 266 10 15 A01AB03 chlorhexidine 2,02 6 -3 930 6 5 A01AB11 various 0,33 21 57 335 21 55 A01AB22 doxycycline - - - 0 - -100 A01AC Corticosteroids for local oral treatment - - - 113 1 -26 A01AC01 triamcinolone - - - 113 1 -26 A01AD Other agents for local oral treatment 0,02 0 -28 49 0 -32 A01AD02 benzydamine 0,02 0 -28 49 0 -32 A02 DRUGS FOR ACID RELATED DISORDERS 73,05 3 3 30 885 4 -5 A02A ANTACIDS 2,23 1 1 3 681 1 3 A02AA Magnesium compounds 0,07 22 -7 141 22 -7 A02AA04 magnesium hydroxide 0,07 22 -7 141 22 -7 A02AD Combinations and complexes of aluminium, 2,17 0 1 3 539 0 4 calcium and magnesium compounds A02AD01 ordinary salt combinations 2,17 0 1 3 539 0 4 A02B DRUGS FOR PEPTIC ULCER AND 70,82 3 3 27 205 5 -7 GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 0,17 7 -77 551 10 -29 A02BA02 ranitidine 0,00 1 -100 1 1 -100 A02BA03 famotidine 0,16 7 48 550 10 43 A02BB Prostaglandins 0,04 62 55 80 62 55 A02BB01 misoprostol 0,04 62 55 80 62 55 A02BC Proton pump inhibitors 69,26 3 4 23 531 4 -8 A02BC01 omeprazole 8,62 2 -2 2 406 3 -5 A02BC02 pantoprazole 37,89 4 6 8 047 8 -15 A02BC03 lansoprazole 5,47 1 -3 1 205 1 -42 Page 2 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

A02BC04 rabeprazole 1,59 1 8 922 1 8 A02BC05 esomeprazole 15,68 2 5 10 950 3 3 A02BD Combinations for eradication of Helicobacter pylori 0,02 0 -35 218 0 -28 A02BD03 lansoprazole, metronidazole and amoxicillin 0,00 0 -69 23 0 -69 A02BD07 lansoprazole, amoxicillin and clarithromycin 0,02 0 -14 196 0 -14 A02BX Other drugs for peptic ulcer and 1,33 8 11 2 825 7 17 gastro-oesophageal reflux disease (GORD) A02BX02 sucralfate 0,35 22 20 574 21 21 A02BX13 alginic acid 0,98 3 7 2 251 3 16 A03 DRUGS FOR FUNCTIONAL 2,67 10 -2 5 455 46 -7 GASTROINTESTINAL DISORDERS A03A DRUGS FOR FUNCTIONAL 1,17 7 -5 1 895 19 1 GASTROINTESTINAL DISORDERS A03AB Synthetic anticholinergics, quaternary ammonium 0,05 87 -3 372 87 -3 compounds A03AB02 glycopyrronium bromide 0,05 87 -3 372 87 -3 A03AX Other drugs for functional gastrointestinal disorders 1,12 3 -5 1 523 2 2 A03AX13 silicones 1,12 3 -5 1 389 3 -6 A03AX15 menthae piperitae aetheroleum - - - 135 0 640 A03B BELLADONNA AND DERIVATIVES, PLAIN 0,04 93 -34 344 93 -47 A03BA Belladonna alkaloids, tertiary amines 0,04 93 -36 285 92 -49 A03BA01 atropine 0,04 93 -36 285 92 -49 A03BB Belladonna alkaloids semisynthetic, quaternary 0,00 97 0 59 96 -32 ammonium compounds A03BB01 butylscopolamine 0,00 97 0 59 96 -32 A03C ANTISPASMODICS IN COMBINATION WITH 0,18 1 -11 196 1 -12 PSYCHOLEPTICS A03CA Synthetic anticholinergic agents in combination 0,18 1 -11 196 1 -12 with psycholeptics A03CA02 clidinium and psycholeptics 0,18 1 -11 196 1 -12 A03D ANTISPASMODICS IN COMBINATION WITH 0,26 11 13 2 599 64 -4 ANALGESICS A03DA Synthetic anticholinergic agents in combination 0,26 11 13 2 599 64 -4 with analgesics Page 3 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

A03DA02 pitofenone and analgesics 0,26 11 13 2 599 64 -4 A03F PROPULSIVES 1,01 11 1 421 35 9 A03FA Propulsives 1,01 11 1 421 35 9 A03FA01 metoclopramide 1,01 11 1 421 35 9 A04 ANTIEMETICS AND ANTINAUSEANTS 0,30 43 2 4 860 48 16 A04A ANTIEMETICS AND ANTINAUSEANTS 0,30 43 2 4 860 48 16 A04AA Serotonin (5HT3) antagonists 0,24 47 2 4 128 48 23 A04AA01 ondansetron 0,16 47 6 1 864 65 86 A04AA02 granisetron 0,06 43 -4 851 41 -2 A04AA05 palonosetron 0,01 100 -16 257 99 -13 A04AA55 palonosetron, combinations 0,01 15 7 1 157 15 -2 A04AD Other antiemetics 0,06 28 2 731 49 -14 A04AD01 scopolamine 0,06 26 5 373 26 24 A04AD12 aprepitant 0,01 50 -13 359 73 -32 A04AD14 rolapitant - - -100 0 - -100 A05 BILE AND LIVER THERAPY 0,92 3 -2 1 414 3 -37 A05A BILE THERAPY 0,92 3 -2 1 414 3 -37 A05AA Bile acids and derivatives 0,92 3 -2 1 414 3 -37 A05AA02 ursodeoxycholic acid 0,92 3 -2 1 342 3 -39 A05AA04 obeticholic acid 0,00 4 108 72 4 108 A06 DRUGS FOR CONSTIPATION 51,34 8 7 29 145 11 7 A06A DRUGS FOR CONSTIPATION 51,34 8 7 29 145 11 7 A06AB Contact laxatives 6,31 5 2 3 740 7 -1 A06AB02 bisacodyl 0,71 2 -22 265 2 -27 A06AB06 senna glycosides 0,13 0 -14 52 0 -13 A06AB08 sodium picosulfate 5,48 6 7 2 819 4 5 A06AB56 senna glycosides, combinations - - - 163 0 -3 A06AB58 sodium picosulfate, combinations 0,00 30 -12 441 31 -13 A06AC Bulk-forming laxatives 12,01 1 12 5 859 2 11 A06AC01 ispaghula (psylla seeds) 11,43 1 13 5 629 2 11 A06AC51 ispaghula, combinations 0,59 1 -3 230 1 -3 A06AD Osmotically acting laxatives 31,51 11 7 16 138 12 9 A06AD11 lactulose 13,23 9 -1 2 630 9 -3 A06AD15 macrogol 17,20 13 16 11 751 12 15 Page 4 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

A06AD17 sodium phosphate - - - 41 18 -25 A06AD65 macrogol, combinations 1,08 3 -13 1 716 21 -3 A06AG Enemas 1,31 10 -4 2 419 17 -4 A06AG02 bisacodyl 0,24 33 -2 414 32 -2 A06AG10 docusate sodium, incl. combinations 0,06 49 -7 555 45 -6 A06AG11 laurilsulfate, incl. combinations 1,01 3 -4 1 450 2 -4 A06AH Peripheral opioid receptor antagonists 0,13 28 22 756 39 21 A06AH01 methylnaltrexone bromide 0,00 97 12 133 97 12 A06AH03 naloxegol 0,13 26 22 624 26 24 A06AX Other drugs for constipation 0,06 9 36 233 11 29 A06AX04 linaclotide 0,03 1 71 111 1 69 A06AX05 prucalopride 0,02 20 7 122 20 7 A07 ANTIDIARRHEALS, INTESTINAL 14,08 2 0 29 004 5 -2 ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS A07A INTESTINAL ANTIINFECTIVES 0,17 21 21 2 666 34 11 A07AA Antibiotics 0,17 21 21 2 666 34 11 A07AA02 nystatin 0,07 18 6 679 18 2 A07AA09 vancomycin 0,01 53 0 687 53 -2 A07AA11 rifaximin 0,09 20 40 1 026 20 40 A07AA12 fidaxomicin 0,00 73 -6 274 73 -6 A07B INTESTINAL ADSORBENTS 0,14 55 9 668 54 -1 A07BA Charcoal preparations 0,14 55 9 668 54 -1 A07BA01 medicinal charcoal 0,14 55 9 668 54 -1 A07C ELECTROLYTES WITH CARBOHYDRATES 0,01 5 -40 138 5 -40 A07CA Oral rehydration salt formulations 0,01 5 -40 138 5 -40 A07D ANTIPROPULSIVES 1,20 2 -12 3 788 1 -14 A07DA Antipropulsives 1,20 2 -12 3 788 1 -14 A07DA03 loperamide 1,20 2 -12 2 962 1 -13 A07DA06 eluxadoline - - -100 0 - -100 A07DA53 loperamide, combinations - - - 825 0 -19 A07E INTESTINAL ANTIINFLAMMATORY AGENTS 11,75 1 5 18 973 1 6 A07EA Corticosteroids acting locally 0,85 3 7 1 976 3 8 A07EA06 budesonide 0,85 3 7 1 976 3 8 A07EC Aminosalicylic acid and similar agents 10,90 1 5 16 997 1 5 Page 5 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

A07EC01 sulfasalazine 3,26 1 2 2 937 1 2 A07EC02 mesalazine 7,63 1 6 14 046 1 6 A07EC03 olsalazine 0,01 3 -31 14 3 -31 A07F ANTIDIARRHEAL MICROORGANISMS 0,82 4 -31 2 473 4 -31 A07FA Antidiarrheal microorganisms 0,82 4 -31 2 473 4 -31 A07FA01 lactic acid producing organisms - - -100 0 - -100 A07FA02 saccharomyces boulardii 0,82 4 -31 2 473 4 -31 A07X OTHER ANTIDIARRHEALS - - - 299 7 -34 A07XA Other antidiarrheals - - - 299 7 -34 A07XA04 racecadotril - - - 299 7 -34 A08 ANTIOBESITY PREPARATIONS, EXCL. DIET 0,07 0 -15 602 0 -6 PRODUCTS A08A ANTIOBESITY PREPARATIONS, EXCL. DIET 0,07 0 -15 602 0 -6 PRODUCTS A08AA Centrally acting antiobesity products - - - 334 0 -6 A08AA62 bupropion and naltrexone - - - 334 0 -6 A08AB Peripherally acting antiobesity products 0,07 0 -15 268 0 -5 A08AB01 orlistat 0,07 0 -15 268 0 -5 A09 DIGESTIVES, INCL. ENZYMES 1,86 4 0 3 146 4 -2 A09A DIGESTIVES, INCL. ENZYMES 1,86 4 0 3 146 4 -2 A09AA Enzyme preparations 1,86 4 0 3 146 4 -2 A09AA02 multienzymes (lipase, protease etc.) 1,86 4 0 3 146 4 -2 A10 DRUGS USED IN DIABETES 107,69 2 1 170 877 2 6 A10A INSULINS AND ANALOGUES 31,24 3 -3 58 326 3 -5 A10AB Insulins and analogues for injection, fast-acting 10,66 3 0 15 325 3 -1 A10AB01 insulin (human) 0,07 41 -14 71 41 -14 A10AB04 insulin lispro 1,56 2 -6 1 774 2 -11 A10AB05 insulin aspart 8,53 3 1 12 730 3 1 A10AB06 insulin glulisine 0,49 2 -2 750 2 -2 A10AC Insulins and analogues, intermediate-acting 0,52 8 -19 736 9 -18 A10AC01 insulin (human) 0,52 8 -19 736 9 -18 A10AD Insulins and analogues, intermediate-acting 0,28 4 -21 466 4 -21 combined with fast-acting A10AD04 insulin lispro 0,02 3 -24 26 3 -24 Page 6 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

A10AD05 insulin aspart 0,27 4 -21 441 4 -21 A10AE Insulins and analogues, long-acting 19,79 2 -4 41 798 2 -5 A10AE04 insulin glargine 12,26 3 -6 24 527 3 -6 A10AE05 insulin detemir 4,39 2 -21 9 760 2 -26 A10AE06 insulin degludec 3,14 1 55 7 511 1 54 A10AE54 insulin glargine and lixisenatide - - -100 0 - -100 A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. 76,45 1 3 112 551 1 12 INSULINS A10BA Biguanides 33,63 1 1 11 393 1 -2 A10BA02 metformin 33,63 1 1 11 393 1 -2 A10BB Sulfonylureas 0,88 1 -21 87 2 -21 A10BB12 glimepiride 0,88 1 -21 87 2 -21 A10BD Combinations of oral blood glucose lowering drugs 6,28 1 1 13 689 1 1 A10BD05 metformin and pioglitazone - - -100 0 - -100 A10BD07 metformin and sitagliptin 4,08 1 -4 8 464 1 -5 A10BD08 metformin and vildagliptin 0,55 0 -7 1 221 0 -7 A10BD09 pioglitazone and alogliptin 0,01 0 -10 18 0 -10 A10BD10 metformin and saxagliptin 0,02 0 -7 34 0 -7 A10BD11 metformin and linagliptin 0,21 1 4 471 1 4 A10BD13 metformin and alogliptin 0,01 0 -46 12 0 -46 A10BD15 metformin and dapagliflozin 0,50 0 18 1 156 0 18 A10BD19 linagliptin and empagliflozin 0,07 0 17 292 0 17 A10BD20 metformin and empagliflozin 0,84 0 31 1 976 0 31 A10BD21 saxagliptin and dapagliflozin 0,01 0 4 38 0 4 A10BD23 metformin and ertugliflozin 0,00 0 97 2 0 94 A10BD24 sitagliptin and ertugliflozin 0,00 0 22 7 0 24 A10BG Thiazolidinediones 0,51 1 -4 707 1 0 A10BG03 pioglitazone 0,51 1 -4 707 1 0 A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors 12,70 2 -5 27 074 2 -5 A10BH01 sitagliptin 7,44 2 -5 16 187 2 -5 A10BH02 vildagliptin 0,87 2 -10 1 792 2 -10 A10BH03 saxagliptin 0,05 1 -9 108 1 -10 A10BH04 alogliptin 0,03 0 -10 61 0 -11 A10BH05 linagliptin 4,31 3 -4 8 926 3 -4 Page 7 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

A10BJ Glucagon-like peptide-1 (GLP-1) analogues 11,35 1 4 32 819 1 37 A10BJ01 exenatide 6,30 1 -17 2 073 1 -19 A10BJ02 liraglutide 1,77 1 -15 12 084 1 -15 A10BJ03 lixisenatide 0,00 2 -27 22 2 -27 A10BJ05 dulaglutide 0,79 1 23 3 761 1 22 A10BJ06 semaglutide 2,49 0 310 14 879 1 263 A10BK Sodium-glucose co-transporter 2 (SGLT2) 10,96 1 25 26 698 1 24 inhibitors A10BK01 dapagliflozin 3,57 1 17 8 383 1 17 A10BK02 canagliflozin 0,19 0 1 392 572 0 1 147 A10BK03 empagliflozin 7,19 1 26 17 711 1 24 A10BK04 ertugliflozin 0,01 0 61 32 0 31 A10BX Other blood glucose lowering drugs, excl. insulins 0,14 1 -9 84 1 22 A10BX02 repaglinide 0,14 1 -9 84 1 22 A11 VITAMINS 17,36 4 12 9 368 14 3 A11C VITAMIN A AND D, INCL. COMBINATIONS OF 6,10 1 46 1 043 2 14 THE TWO A11CC Vitamin D and analogues 6,10 1 46 1 043 2 14 A11CC01 ergocalciferol (vitamin D2) - - - 0 - -100 A11CC02 dihydrotachysterol 0,01 2 -72 19 2 -72 A11CC03 alfacalcidol 0,46 3 8 433 4 9 A11CC05 colecalciferol (vitamin D3) 5,63 1 52 591 1 31 A11D VITAMIN B1, PLAIN AND IN COMBINATION 4,65 13 -8 2 263 55 2 WITH VITAMIN B6 AND B12 A11DA Vitamin B1, plain 0,50 99 4 1 219 99 12 A11DA01 thiamine (vit B1) 0,50 99 4 1 219 99 12 A11DB Vitamin B1 in comb. with vitamin B6 and/or 4,15 2 -9 1 044 3 -9 vitamin B12 A11E VITAMIN B-COMPLEX, INCL. COMBINATIONS 4,35 2 -1 5 697 1 1 A11EA Vitamin B-complex 2,62 4 -2 995 4 -2 A11EX Vitamin B-complex, other combinations 1,72 0 0 4 702 0 1 A11G ASCORBIC ACID (VITAMIN C), INCL. 2,06 1 28 138 1 28 COMBINATIONS A11GA Ascorbic acid (vit C), plain 2,06 1 28 138 1 28 Page 8 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

A11GA01 ascorbic acid (vit C) 2,06 1 28 138 1 28 A11H OTHER PLAIN VITAMIN PREPARATIONS 0,21 8 -17 227 4 7 A11HA Other plain vitamin preparations 0,21 8 -17 227 4 7 A11HA02 pyridoxine (vit B6) 0,13 12 -12 43 12 -12 A11HA03 tocopherol (vit E) 0,08 2 -23 18 2 -23 A11HA08 tocofersolan 0,00 100 - 3 100 - A11HA30 dexpanthenol - - - 164 1 17 A12 MINERAL SUPPLEMENTS 40,12 3 3 16 449 4 4 A12A CALCIUM 34,01 2 3 11 382 2 5 A12AA Calcium 1,13 1 4 852 1 4 A12AA04 calcium carbonate 1,13 1 5 846 1 6 A12AA06 calcium lactate gluconate 0,00 6 -64 6 6 -60 A12AX Calcium, combinations with vitamin D and/or other 32,88 2 3 10 530 2 5 drugs A12B POTASSIUM 6,00 7 4 4 982 9 2 A12BA Potassium 6,00 7 4 4 982 9 2 A12BA01 potassium chloride 6,00 7 5 4 982 9 4 A12BA51 potassium chloride, combinations - - -100 0 - -100 A12C OTHER MINERAL SUPPLEMENTS 0,11 32 -7 86 32 -7 A12CA Sodium 0,11 32 -7 86 32 -7 A12CA01 sodium chloride 0,11 32 -7 86 32 -7 A14 ANABOLIC AGENTS FOR SYSTEMIC USE 0,02 24 -6 13 24 -6 A14A ANABOLIC STEROIDS 0,02 24 -6 13 24 -6 A14AB Estren derivatives 0,02 24 -6 13 24 -6 A14AB01 nandrolone 0,02 24 -6 13 24 -6 A16 OTHER ALIMENTARY TRACT AND 0,03 48 31 18 281 39 16 METABOLISM PRODUCTS A16A OTHER ALIMENTARY TRACT AND 0,03 48 31 18 281 39 16 METABOLISM PRODUCTS A16AA Amino acids and derivatives 0,00 63 4 665 162 83 4 265 A16AA04 mercaptamine 0,00 0 - 22 0 - A16AA05 carglumic acid 0,00 100 2 890 135 100 3 520 A16AA06 betaine 0,00 0 - 6 0 - A16AB Enzymes 0,02 61 21 13 480 44 9 Page 9 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

A16AB02 imiglucerase 0,00 15 -18 738 15 -18 A16AB03 agalsidase alfa 0,00 47 -8 1 670 47 -10 A16AB04 agalsidase beta 0,01 45 15 9 230 45 12 A16AB05 laronidase 0,00 100 -1 258 100 -1 A16AB07 alglucosidase alfa 0,01 100 56 619 100 56 A16AB10 velaglucerase alfa 0,00 0 33 965 0 33 A16AX Various alimentary tract and metabolism products 0,01 24 34 4 638 25 39 A16AX03 sodium phenylbutyrate 0,00 1 -1 220 1 -1 A16AX04 nitisinone 0,00 1 11 510 1 10 A16AX05 zinc acetate 0,00 67 - 1 67 - A16AX06 miglustat 0,00 0 17 236 0 13 A16AX08 teduglutide 0,00 100 444 616 100 306 A16AX09 glycerol phenylbutyrate 0,00 0 23 175 0 23 A16AX10 eliglustat 0,00 0 5 1 114 0 5 A16AX12 trientine 0,00 100 3 200 488 100 3 156 A16AX14 migalastat 0,00 0 23 1 217 0 21 A16AX15 telotristat 0,00 96 -6 60 96 -6 B BLOOD AND BLOOD FORMING ORGANS 141,06 4 3 285 046 27 6 B01 ANTITHROMBOTIC AGENTS 116,20 4 1 155 561 12 12 B01A ANTITHROMBOTIC AGENTS 116,20 4 1 155 561 12 12 B01AA Vitamin K antagonists 8,18 2 -19 1 877 2 -19 B01AA03 warfarin 8,18 2 -19 1 877 2 -19 B01AB Heparin group 6,63 36 -1 23 313 39 -6 B01AB01 heparin 0,08 99 0 821 99 7 B01AB02 antithrombin 0,00 100 -8 381 100 -5 B01AB04 dalteparin 0,48 7 2 1 273 8 4 B01AB05 enoxaparin 5,01 40 -2 14 592 41 -8 B01AB09 danaparoid 0,00 100 -85 160 100 -24 B01AB10 tinzaparin 1,06 21 1 6 086 28 -3 B01AC Platelet aggregation inhibitors excl. heparin 77,47 2 -1 20 398 5 3 B01AC04 clopidogrel 10,34 3 9 1 565 21 12 B01AC06 acetylsalicylic acid 62,32 1 -2 7 323 1 0 B01AC07 dipyridamole 0,18 2 -51 156 2 -51 B01AC11 iloprost 0,00 48 -13 256 47 -14 Page 10 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

B01AC13 abciximab 0,00 100 -114 -13 100 -114 B01AC16 eptifibatide 0,00 100 -18 90 100 -18 B01AC17 tirofiban 0,00 100 -22 27 100 -22 B01AC21 treprostinil 0,00 2 9 2 158 3 5 B01AC22 prasugrel 0,03 14 60 119 15 61 B01AC24 ticagrelor 0,85 4 2 3 538 4 2 B01AC25 cangrelor 0,00 100 -19 147 100 -19 B01AC27 selexipag 0,00 0 20 788 0 1 B01AC30 combinations 3,74 2 -11 4 245 2 17 B01AD Enzymes 0,00 100 11 5 035 100 7 B01AD02 alteplase 0,00 100 1 4 075 100 1 B01AD11 tenecteplase 0,00 99 39 960 99 39 B01AE Direct thrombin inhibitors 2,87 2 3 12 618 3 2 B01AE03 argatroban 0,00 100 56 83 100 53 B01AE06 bivalirudin 0,00 100 -44 104 100 -44 B01AE07 dabigatran etexilate 2,87 2 3 12 431 2 2 B01AF Direct factor Xa inhibitors 21,02 2 25 91 106 3 23 B01AF01 rivaroxaban 9,11 2 15 37 647 2 14 B01AF02 apixaban 10,67 3 32 47 651 3 29 B01AF03 edoxaban 1,24 2 50 5 808 3 51 B01AX Other antithrombotic agents 0,03 10 -9 1 214 85 48 B01AX01 defibrotide 0,00 100 17 716 100 17 B01AX05 fondaparinux 0,03 9 -10 193 9 -5 B01AX07 caplacizumab 0,00 100 - 305 100 - B02 ANTIHEMORRHAGICS 0,34 21 15 55 145 27 -2 B02A ANTIFIBRINOLYTICS 0,27 18 15 2 266 75 18 B02AA Amino acids 0,27 17 14 2 016 72 15 B02AA02 tranexamic acid 0,27 17 14 2 016 72 15 B02AB Proteinase inhibitors 0,00 100 54 250 100 46 B02AB01 aprotinin 0,00 100 61 190 100 61 B02AB02 alfa1 antitrypsin 0,00 100 13 61 100 13 B02B VITAMIN K AND OTHER HEMOSTATICS 0,07 34 16 52 879 25 -3 B02BA Vitamin K 0,02 90 0 118 88 -21 B02BA01 phytomenadione 0,02 90 0 118 88 -21 Page 11 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

B02BB Fibrinogen 0,00 100 -3 1 867 100 0 B02BB01 fibrinogen, human 0,00 100 -3 1 867 100 0 B02BC Local hemostatics - - - 3 172 100 -8 B02BC30 combinations - - - 3 172 100 -8 B02BD Blood coagulation factors - - - 40 028 19 -7 B02BD01 coagulation factor IX, II, VII and X in combination - - - 4 420 100 -4 B02BD02 coagulation factor VIII - - - 24 213 5 -5 B02BD03 factor VIII inhibitor bypassing activity - - - 831 37 -57 B02BD04 coagulation factor IX - - - 5 447 7 -6 B02BD06 von Willebrand factor and coagulation factor VIII in - - - 3 851 17 -8 combination B02BD07 coagulation factor XIII - - - 730 37 20 B02BD08 coagulation factor VIIa - - - 483 79 39 B02BD10 von Willebrand factor - - - 52 67 - B02BX Other systemic hemostatics 0,05 8 26 7 694 7 35 B02BX04 romiplostim 0,01 9 33 1 805 8 31 B02BX05 eltrombopag 0,03 9 22 4 518 9 20 B02BX06 emicizumab 0,00 2 145 1 371 2 145 B03 ANTIANEMIC PREPARATIONS 24,52 6 17 35 629 41 1 B03A IRON PREPARATIONS 5,94 5 -2 16 412 77 -2 B03AA Iron bivalent, oral preparations 4,14 3 0 2 332 2 -33 B03AA01 ferrous glycine sulfate 3,24 3 6 1 904 2 -35 B03AA07 ferrous sulfate 0,90 3 -18 429 3 -27 B03AB Iron trivalent, oral preparations 1,63 2 -7 1 349 3 -5 B03AB05 ferric oxide polymaltose complexes 1,63 2 -7 1 343 3 -5 B03AB10 ferric maltol 0,00 0 43 6 0 43 B03AC Iron, parenteral preparations 0,17 98 3 12 731 98 8 B03AD Iron in combination with folic acid - - - 0 - -100 B03AD01 ferrous amino acid complex - - - 0 - -100 B03B VITAMIN B12 AND FOLIC ACID 17,35 6 26 2 181 6 8 B03BA Vitamin B12 (cyanocobalamin and derivatives) 5,69 6 -6 1 095 5 -6 B03BA01 cyanocobalamin 1,10 1 -4 369 1 -4 B03BA03 hydroxocobalamin 4,58 7 -6 726 7 -6 B03BB Folic acid, combinations 11,66 5 51 1 086 6 26 Page 12 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

B03BB01 folic acid 11,66 5 51 1 086 6 26 B03X OTHER ANTIANEMIC PREPARATIONS 1,23 11 4 17 036 11 3 B03XA Other antianemic preparations 1,23 11 4 17 036 11 3 B03XA01 erythropoietin 0,21 17 14 2 440 18 16 B03XA02 darbepoetin alfa 0,85 10 4 12 364 10 4 B03XA03 methoxy polyethylene glycolepoetin beta 0,17 9 -5 2 232 9 -13 B05 BLOOD SUBSTITUTES AND PERFUSION - - - 30 643 81 -2 SOLUTIONS B05A BLOOD AND RELATED PRODUCTS - - - 5 770 100 11 B05AA Blood substitutes and plasma protein fractions - - - 5 770 100 11 B05AA01 albumin - - - 5 758 100 12 B05AA06 gelatin agents - - - 12 97 -37 B05AA07 hydroxyethylstarch - - - 0 100 -98 B05B I.V. SOLUTIONS - - - 17 302 99 -3 B05BA Solutions for parenteral nutrition - - - 5 440 100 6 B05BA01 amino acids - - - 78 100 -20 B05BA02 fat emulsions - - - 40 96 -5 B05BA03 carbohydrates - - - 443 99 0 B05BA10 combinations - - - 4 879 100 7 B05BB Solutions affecting the electrolyte balance - - - 11 831 99 -7 B05BB01 electrolytes - - - 11 008 99 -6 B05BB02 electrolytes with carbohydrates - - - 823 100 -10 B05BC Solutions producing osmotic diuresis - - - 32 98 13 B05BC01 mannitol - - - 32 98 13 B05D PERITONEAL DIALYTICS - - - 6 118 6 -10 B05DA Isotonic solutions - - - 2 558 6 -7 B05DB Hypertonic solutions - - - 3 560 6 -12 B05X I.V. SOLUTION ADDITIVES - - - 1 210 99 -4 B05XA Electrolyte solutions - - - 786 98 -5 B05XA01 potassium chloride - - - 232 99 -18 B05XA03 sodium chloride - - - 131 92 -26 B05XA05 magnesium sulfate - - - 107 100 31 B05XA06 potassium phosphate, incl. comb. with other - - - 34 99 9 potassium salts Page 13 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

B05XA07 calcium chloride - - - 27 100 - B05XA14 sodium glycerophosphate - - - 58 96 -10 B05XA31 electrolytes in combination with other drugs - - - 197 100 3 B05XB Amino acids - - - 27 100 -13 B05XB02 alanyl glutamine - - - 27 100 -13 B05XC Vitamins - - - 397 100 -1 B05Z HEMODIALYTICS AND HEMOFILTRATES - - - 242 100 20 B05ZB Hemofiltrates - - - 242 100 20 B06 OTHER HEMATOLOGICAL AGENTS 0,00 40 23 8 067 34 12 B06A OTHER HEMATOLOGICAL AGENTS 0,00 40 23 8 067 34 12 B06AB Heme products - - - 15 100 - B06AB01 hemin - - - 15 100 - B06AC Drugs used in hereditary angioedema 0,00 40 23 8 052 34 12 B06AC01 c1-inhibitor, plasma derived 0,00 20 12 4 425 20 12 B06AC02 icatibant 0,00 11 -29 2 025 11 -29 B06AC04 conestat alfa 0,00 100 -61 96 100 -65 B06AC05 lanadelumab 0,00 100 950 1 506 100 950 C CARDIOVASCULAR SYSTEM 654,67 2 5 138 299 14 -8 C01 CARDIAC THERAPY 12,87 8 -4 22 465 62 2 C01A CARDIAC GLYCOSIDES 1,91 4 -8 1 052 15 -5 C01AA Digitalis glycosides 1,91 4 -8 1 052 15 -5 C01AA05 digoxin 1,91 4 -8 1 052 15 -5 C01B ANTIARRHYTHMICS, CLASS I AND III 1,97 3 -2 2 862 41 -23 C01BB Antiarrhythmics, class IB 0,00 97 -18 283 97 -21 C01BB01 lidocaine 0,00 97 -18 283 97 -21 C01BC Antiarrhythmics, class IC 1,40 1 -1 1 177 2 -28 C01BC04 flecainide 1,40 1 -1 1 177 2 -28 C01BD Antiarrhythmics, class III 0,57 10 -2 668 23 -29 C01BD01 amiodarone 0,46 12 -1 260 28 -15 C01BD05 ibutilide 0,00 100 -30 77 100 -30 C01BD07 dronedarone 0,11 1 -7 331 1 -38 C01BG Other antiarrhythmics, class I and III 0,00 100 -6 733 100 -6 C01BG11 vernakalant 0,00 100 -6 733 100 -6 C01C CARDIAC STIMULANTS EXCL. CARDIAC 0,69 83 12 13 277 85 13 GLYCOSIDES Page 14 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

C01CA Adrenergic and dopaminergic agents 0,69 83 12 8 130 75 23 C01CA01 etilefrine 0,06 23 5 259 62 -38 C01CA02 isoprenaline 0,00 100 - 138 100 - C01CA03 norepinephrine 0,08 99 39 2 302 100 69 C01CA04 dopamine 0,00 93 31 139 93 80 C01CA06 phenylephrine 0,02 99 -19 676 99 13 C01CA07 dobutamine 0,00 100 57 88 100 59 C01CA17 midodrine 0,01 15 57 65 17 57 C01CA24 epinephrine 0,52 88 10 4 175 56 11 C01CA26 ephedrine - - - 288 98 -5 C01CE Phosphodiesterase inhibitors 0,00 100 16 819 100 11 C01CE02 milrinone 0,00 100 16 819 100 11 C01CX Other cardiac stimulants 0,00 100 -2 4 328 100 -2 C01CX08 levosimendan 0,00 100 -2 4 328 100 -2 C01D VASODILATORS USED IN CARDIAC DISEASES 8,27 4 -4 4 561 12 -1 C01DA Organic nitrates 8,27 4 -4 4 561 12 -1 C01DA02 glyceryl trinitrate 0,52 27 -5 1 018 41 3 C01DA08 isosorbide dinitrate 1,04 4 -7 991 8 -5 C01DA14 isosorbide mononitrate 6,71 3 -3 2 553 3 -1 C01E OTHER CARDIAC PREPARATIONS 0,03 49 -15 714 95 -19 C01EA Prostaglandins 0,00 100 -13 287 100 -13 C01EA01 alprostadil 0,00 100 -13 287 100 -13 C01EB Other cardiac preparations 0,03 49 -15 427 92 -22 C01EB10 adenosine 0,01 99 -37 222 98 -39 C01EB16 ibuprofen 0,00 100 - 9 100 - C01EB17 ivabradine 0,02 4 17 33 6 -7 C01EB21 regadenoson 0,00 100 7 162 100 7 C02 ANTIHYPERTENSIVES 3,18 3 -1 9 120 7 16 C02A ANTIADRENERGIC AGENTS, CENTRALLY 2,61 3 -3 1 523 31 7 ACTING C02AC Imidazoline receptor agonists 2,61 3 -3 1 523 31 7 C02AC01 clonidine 0,06 35 -3 460 89 27 C02AC02 guanfacine 0,07 14 51 439 13 42 C02AC05 moxonidine 2,48 1 -4 624 1 -16 Page 15 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

C02C ANTIADRENERGIC AGENTS, PERIPHERALLY 0,51 4 7 404 4 6 ACTING C02CA Alpha-adrenoceptor blocking agents 0,51 4 7 404 4 6 C02CA01 prazosin 0,51 4 7 404 4 6 C02K OTHER ANTIHYPERTENSIVES 0,06 2 11 7 193 2 19 C02KX Antihypertensives for pulmonary arterial 0,06 2 11 7 193 2 19 hypertension C02KX01 bosentan 0,01 3 2 1 317 3 62 C02KX02 ambrisentan 0,01 1 -5 797 1 2 C02KX04 macitentan 0,02 2 10 3 416 2 10 C02KX05 riociguat 0,02 1 28 1 664 2 21 C03 DIURETICS 50,51 6 -2 9 149 22 5 C03A LOW-CEILING DIURETICS, THIAZIDES 7,11 2 7 1 429 2 10 C03AA Thiazides, plain 7,11 2 7 1 429 2 10 C03AA03 hydrochlorothiazide 7,11 2 7 1 429 2 10 C03B LOW-CEILING DIURETICS, EXCL. THIAZIDES 0,49 3 3 235 15 27 C03BA Sulfonamides, plain 0,49 3 3 235 15 27 C03BA08 metolazone 0,01 61 - 52 61 - C03BA11 indapamide 0,48 2 0 183 2 -1 C03C HIGH-CEILING DIURETICS 34,95 7 -1 5 245 35 4 C03CA Sulfonamides, plain 34,95 7 -1 5 245 35 4 C03CA01 furosemide 34,95 7 -1 5 245 35 4 C03D POTASSIUM-SPARING AGENTS 2,92 3 9 1 497 3 9 C03DA Aldosterone antagonists 2,92 3 9 1 497 3 9 C03DA01 spironolactone 2,91 3 8 1 413 3 9 C03DA04 eplerenone 0,01 2 15 84 2 14 C03E DIURETICS AND POTASSIUM-SPARING 5,03 1 -20 609 1 -16 AGENTS IN COMBINATION C03EA Low-ceiling diuretics and potassium-sparing 4,37 1 -21 487 1 -17 agents C03EA01 hydrochlorothiazide and potassium-sparing agents 4,37 1 -21 487 1 -17 C03EB High-ceiling diuretics and potassium-sparing 0,67 4 -11 122 4 -11 agents C03EB01 furosemide and potassium-sparing agents 0,67 4 -11 122 4 -11 Page 16 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

C03X OTHER DIURETICS 0,00 1 1 477 135 20 331 C03XA Vasopressin antagonists 0,00 1 1 477 135 20 331 C03XA01 tolvaptan 0,00 1 1 477 135 20 331 C04 PERIPHERAL VASODILATORS 0,11 5 2 78 5 2 C04A PERIPHERAL VASODILATORS 0,11 5 2 78 5 2 C04AD Purine derivatives 0,11 5 2 78 5 2 C04AD03 pentoxifylline 0,11 5 2 78 5 2 C05 VASOPROTECTIVES - - - 4 518 6 1 C05A AGENTS FOR TREATMENT OF - - - 2 788 2 0 HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids - - - 2 649 2 3 C05AA01 hydrocortisone - - - 79 30 33 C05AA04 prednisolone - - - 2 133 1 4 C05AA08 fluocortolone - - - 437 1 -3 C05AE Muscle relaxants - - - 139 1 4 C05AE01 glyceryl trinitrate - - - 139 1 4 C05AX Other agents for treatment of hemorrhoids and - - - 0 - -100 anal fissures for topical use C05AX03 other preparations, combinations - - - 0 - -100 C05B ANTIVARICOSE THERAPY - - - 1 730 11 3 C05BA Heparins or heparinoids for topical use - - - 1 538 2 1 C05BA01 organo-heparinoid - - - 1 538 2 1 C05BB Sclerosing agents for local injection - - - 192 87 14 C05BB02 polidocanol - - - 192 87 14 C07 BETA BLOCKING AGENTS 65,79 2 2 19 295 4 -5 C07A BETA BLOCKING AGENTS 61,41 2 3 17 233 5 -3 C07AA Beta blocking agents, non-selective 2,68 2 -2 1 443 2 4 C07AA05 propranolol 2,22 2 0 1 307 2 5 C07AA07 sotalol 0,46 1 -8 136 1 -8 C07AB Beta blocking agents, selective 56,70 2 4 14 743 3 -3 C07AB02 metoprolol 9,70 2 -3 3 881 5 -17 C07AB03 atenolol 1,91 2 5 383 2 5 C07AB04 acebutolol 0,11 2 -20 59 2 -20 Page 17 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

C07AB05 betaxolol 0,25 1 -60 90 1 -60 C07AB07 bisoprolol 42,23 2 7 9 678 2 5 C07AB08 celiprolol 0,71 1 -8 161 1 -8 C07AB09 esmolol 0,00 100 -34 27 100 -1 C07AB12 nebivolol 1,79 1 3 463 1 -4 C07AB14 landiolol - - - 1 100 -57 C07AG Alpha and beta blocking agents 2,03 2 -5 1 047 41 -11 C07AG01 labetalol 0,05 13 -45 503 83 -15 C07AG02 carvedilol 1,98 2 -3 543 2 -7 C07B BETA BLOCKING AGENTS AND THIAZIDES 3,06 0 -10 1 048 0 -12 C07BB Beta blocking agents, selective, and thiazides 3,06 0 -10 1 048 0 -12 C07BB02 metoprolol and thiazides 0,32 0 -35 142 0 -37 C07BB07 bisoprolol and thiazides 2,74 0 -5 867 0 -6 C07BB12 nebivolol and thiazides - - - 38 0 -13 C07F BETA BLOCKING AGENTS, OTHER 1,32 1 -6 1 014 1 -20 COMBINATIONS C07FB Beta blocking agent and calcium channel blockers 1,32 1 -6 1 014 1 -20 C07FB02 metoprolol and felodipine 1,32 1 -6 1 014 1 -20 C08 CALCIUM CHANNEL BLOCKERS 99,70 1 5 11 394 4 -11 C08C SELECTIVE CALCIUM CHANNEL BLOCKERS 98,25 1 5 10 509 4 -11 WITH MAINLY VASCULAR EFFECTS C08CA Dihydropyridine derivatives 98,25 1 5 10 509 4 -11 C08CA01 amlodipine 69,57 1 5 4 370 1 4 C08CA02 felodipine 7,56 1 0 2 250 1 -17 C08CA03 isradipine - - -100 0 - -100 C08CA05 nifedipine 0,68 2 -33 506 2 -31 C08CA06 nimodipine 0,00 74 -8 305 95 7 C08CA07 nisoldipine - - -100 0 - -100 C08CA10 nilvadipine 0,71 2 -2 427 2 -2 C08CA13 lercanidipine 19,73 1 9 2 652 1 -23 C08D SELECTIVE CALCIUM CHANNEL BLOCKERS 1,45 3 0 885 2 -10 WITH DIRECT CARDIAC EFFECTS C08DA Phenylalkylamine derivatives 0,75 3 5 243 1 -21 C08DA01 verapamil 0,75 3 5 243 1 -21 Page 18 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

C08DB Benzothiazepine derivatives 0,71 3 -5 641 3 -4 C08DB01 diltiazem 0,71 3 -5 641 3 -4 C09 AGENTS ACTING ON THE 274,80 1 4 38 543 1 -11 RENIN-ANGIOTENSIN SYSTEM C09A ACE INHIBITORS, PLAIN 103,85 1 0 6 223 1 -24 C09AA ACE inhibitors, plain 103,85 1 0 6 223 1 -24 C09AA02 enalapril 21,93 1 0 2 003 1 -2 C09AA03 lisinopril 3,48 1 -4 557 1 -18 C09AA04 perindopril 4,59 1 -2 1 575 1 -8 C09AA05 ramipril 73,82 1 1 2 079 1 -44 C09AA06 quinapril 0,03 2 - 8 2 - C09AA15 zofenopril - - -100 0 - -100 C09B ACE INHIBITORS, COMBINATIONS 11,24 0 -2 3 519 0 -13 C09BA ACE inhibitors and diuretics 9,09 0 -4 2 433 0 -19 C09BA02 enalapril and diuretics 6,02 0 -5 1 223 0 -27 C09BA03 lisinopril and diuretics 1,13 1 -8 529 1 -17 C09BA04 perindopril and diuretics 0,97 1 -2 505 1 -3 C09BA05 ramipril and diuretics 0,94 0 -2 165 0 -2 C09BA06 quinapril and diuretics 0,03 1 - 11 1 - C09BB ACE inhibitors and calcium channel blockers 1,67 0 5 777 0 4 C09BB02 enalapril and lercanidipine 0,36 0 -1 123 0 -2 C09BB04 perindopril and amlodipine 1,32 0 6 654 0 5 C09BX ACE inhibitors, other combinations 0,47 0 14 309 0 6 C09BX01 perindopril, amlodipine and indapamide 0,43 0 14 293 0 6 C09BX02 perindopril and bisoprolol 0,04 0 23 17 0 5 C09C ANGIOTENSIN II RECEPTOR BLOCKERS 125,68 1 9 13 100 1 -7 (ARBs), PLAIN C09CA Angiotensin II receptor blockers (ARBs), plain 125,68 1 9 13 100 1 -7 C09CA01 losartan 49,44 1 5 5 458 1 -16 C09CA02 eprosartan 0,27 2 -23 202 2 -30 C09CA03 valsartan 16,00 1 9 2 146 1 11 C09CA06 candesartan 49,04 1 14 3 927 1 -6 C09CA07 telmisartan 9,80 1 8 986 1 11 C09CA08 olmesartan medoxomil 1,12 1 4 381 1 106 Page 19 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

C09D ANGIOTENSIN II RECEPTOR BLOCKERS 34,03 0 3 15 700 1 -7 (ARBs), COMBINATIONS C09DA Angiotensin II receptor blockers (ARBs) and 29,11 0 2 9 391 0 -2 diuretics C09DA01 losartan and diuretics 12,51 0 -2 3 748 0 -2 C09DA02 eprosartan and diuretics 0,32 0 -8 240 0 -17 C09DA03 valsartan and diuretics 4,53 0 3 1 103 0 -3 C09DA06 candesartan and diuretics 7,52 0 5 3 352 0 -1 C09DA07 telmisartan and diuretics 3,89 1 8 785 0 1 C09DA08 olmesartan medoxomil and diuretics 0,35 0 1 164 0 13 C09DB Angiotensin II receptor blockers (ARBs) and 2,81 0 6 1 369 0 -44 calcium channel blockers C09DB01 valsartan and amlodipine 2,68 0 5 1 284 0 -46 C09DB02 olmesartan medoxomil and amlodipine 0,14 1 28 85 1 25 C09DX Angiotensin II receptor blockers (ARBs), other 2,11 1 12 4 941 2 0 combinations C09DX01 valsartan, amlodipine and hydrochlorothiazide 1,68 0 7 1 183 0 -46 C09DX04 valsartan and sacubitril 0,42 3 37 3 758 3 37 C10 LIPID MODIFYING AGENTS 147,71 1 11 23 736 1 -24 C10A LIPID MODIFYING AGENTS, PLAIN 147,59 1 11 23 544 1 -24 C10AA HMG CoA reductase inhibitors 138,43 1 10 19 190 1 -31 C10AA01 simvastatin 33,39 1 -6 6 679 1 -41 C10AA02 lovastatin 0,31 1 1 229 1 8 C10AA03 pravastatin 1,83 2 -16 1 029 2 -15 C10AA04 fluvastatin 1,76 1 -5 600 2 -19 C10AA05 atorvastatin 63,09 2 13 6 166 1 -27 C10AA07 rosuvastatin 38,06 1 28 4 488 1 -24 C10AB Fibrates 0,52 1 6 417 1 5 C10AB02 bezafibrate 0,07 1 2 88 1 2 C10AB04 gemfibrozil 0,02 3 -21 17 3 -21 C10AB05 fenofibrate 0,42 1 9 311 1 7 C10AC Bile acid sequestrants 0,00 0 -98 15 0 -94 C10AC01 colestyramine - - -100 0 - -100 C10AC04 colesevelam 0,00 0 27 15 0 27 Page 20 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

C10AX Other lipid modifying agents 8,64 1 32 3 922 1 43 C10AX09 ezetimibe 8,54 1 31 1 561 2 -15 C10AX13 evolocumab 0,07 1 161 1 790 1 161 C10AX14 alirocumab 0,03 1 164 571 1 161 C10B LIPID MODIFYING AGENTS, COMBINATIONS 0,13 0 28 191 0 60 C10BA Combinations of various lipid modifying agents - - -100 58 0 383 C10BA02 simvastatin and ezetimibe - - -100 0 - -100 C10BA06 rosuvastatin and ezetimibe - - - 58 0 - C10BX Lipid modifying agents in combination with other 0,13 0 35 134 0 24 drugs C10BX11 atorvastatin, amlodipine and perindopril 0,13 0 35 117 0 11 C10BX15 atorvastatin and perindopril - - - 17 0 677 D DERMATOLOGICALS 2,89 1 -2 43 279 5 0 D01 ANTIFUNGALS FOR DERMATOLOGICAL USE 1,43 1 -9 5 940 3 0 D01A ANTIFUNGALS FOR TOPICAL USE - - - 4 886 3 3 D01AA Antibiotics - - - 47 2 6 D01AA02 natamycin - - - 47 2 6 D01AC Imidazole and triazole derivatives - - - 3 293 4 5 D01AC01 clotrimazole - - - 224 1 -10 D01AC02 miconazole - - - 993 7 1 D01AC07 tioconazole - - - 43 0 116 D01AC08 ketoconazole - - - 1 159 1 9 D01AC10 bifonazole - - - 39 0 - D01AC20 imidazoles/triazoles in combination with - - - 834 7 1 corticosteroids D01AE Other antifungals for topical use - - - 1 546 1 -1 D01AE14 ciclopirox - - - 47 0 -23 D01AE15 terbinafine - - - 1 311 1 1 D01AE16 amorolfine - - - 188 1 -8 D01B ANTIFUNGALS FOR SYSTEMIC USE 1,43 1 -9 1 054 1 -10 D01BA Antifungals for systemic use 1,43 1 -9 1 054 1 -10 D01BA02 terbinafine 1,43 1 -9 1 054 1 -10 D02 EMOLLIENTS AND PROTECTIVES - - - 49 0 -98 D02A EMOLLIENTS AND PROTECTIVES - - - 49 0 -98 Page 21 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

D02AE Carbamide products - - - 29 0 -98 D02AE01 carbamide - - - 29 0 -98 D02AX Other emollients and protectives - - - 20 0 -98 D03 PREPARATIONS FOR TREATMENT OF - - - 6 810 2 2 WOUNDS AND ULCERS D03A CICATRIZANTS - - - 6 810 2 2 D03AX Other cicatrizants - - - 6 810 2 2 D03AX03 dexpanthenol - - - 6 810 2 2 D04 ANTIPRURITICS, INCL. ANTIHISTAMINES, - - - 379 0 -11 ANESTHETICS, ETC. D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, - - - 379 0 -11 ANESTHETICS, ETC. D04AA Antihistamines for topical use - - - 379 0 -11 D04AA04 tripelennamine - - - 379 0 -11 D05 ANTIPSORIATICS 0,17 2 8 2 215 2 3 D05A ANTIPSORIATICS FOR TOPICAL USE - - - 1 908 2 3 D05AX Other antipsoriatics for topical use - - - 1 908 2 3 D05AX02 calcipotriol - - - 44 2 4 D05AX03 calcitriol - - - 29 2 -26 D05AX52 calcipotriol, combinations - - - 1 836 2 3 D05B ANTIPSORIATICS FOR SYSTEMIC USE 0,17 2 8 306 2 5 D05BB Retinoids for treatment of psoriasis 0,17 2 8 306 2 5 D05BB02 acitretin 0,17 2 8 306 2 5 D06 ANTIBIOTICS AND CHEMOTHERAPEUTICS - - - 4 725 3 -5 FOR DERMATOLOGICAL USE D06A ANTIBIOTICS FOR TOPICAL USE - - - 2 226 5 -3 D06AX Other antibiotics for topical use - - - 2 226 5 -3 D06AX01 fusidic acid - - - 1 017 9 -3 D06AX04 neomycin - - - 1 184 2 -3 D06AX09 mupirocin - - - 26 16 -4 D06B CHEMOTHERAPEUTICS FOR TOPICAL USE - - - 2 499 1 -7 D06BB Antivirals - - - 2 152 1 -1 D06BB03 aciclovir - - - 1 130 1 -2 D06BB06 penciclovir - - - 195 0 -21 Page 22 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

D06BB10 imiquimod - - - 632 1 22 D06BB53 aciclovir, combinations - - - 196 0 -25 D06BX Other chemotherapeutics - - - 347 0 -32 D06BX01 metronidazole - - - 342 0 -3 D06BX02 ingenol mebutate - - - 5 4 -97 D07 CORTICOSTEROIDS, DERMATOLOGICAL - - - 12 322 3 4 PREPARATIONS D07A CORTICOSTEROIDS, PLAIN - - - 8 685 3 6 D07AA Corticosteroids, weak (group I) - - - 3 726 1 4 D07AA02 hydrocortisone - - - 3 726 1 4 D07AB Corticosteroids, moderately potent (group II) - - - 1 508 3 16 D07AB01 clobetasone - - - 9 0 0 D07AB02 hydrocortisone butyrate - - - 929 2 8 D07AB08 desonide - - - 570 4 31 D07AC Corticosteroids, potent (group III) - - - 2 675 6 1 D07AC01 betamethasone - - - 1 716 8 5 D07AC03 desoximetasone - - - 32 10 -60 D07AC13 mometasone - - - 891 3 1 D07AC14 methylprednisolone aceponate - - - 36 0 -10 D07AD Corticosteroids, very potent (group IV) - - - 776 3 26 D07AD01 clobetasol - - - 776 3 26 D07B CORTICOSTEROIDS, COMBINATIONS WITH - - - 1 249 3 1 ANTISEPTICS D07BA Corticosteroids, weak, combinations with - - - 728 3 -3 antiseptics D07BA04 hydrocortisone and antiseptics - - - 728 3 -3 D07BB Corticosteroids, moderately potent, combinations - - - 349 3 0 with antiseptics D07BB04 hydrocortisone butyrate and antiseptics - - - 349 3 0 D07BC Corticosteroids, potent, combinations with - - - 172 6 27 antiseptics D07BC01 betamethasone and antiseptics - - - 172 6 27 D07C CORTICOSTEROIDS, COMBINATIONS WITH - - - 1 592 4 -2 ANTIBIOTICS Page 23 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

D07CA Corticosteroids, weak, combinations with - - - 926 4 -2 antibiotics D07CA01 hydrocortisone and antibiotics - - - 926 4 -2 D07CC Corticosteroids, potent, combinations with - - - 666 4 -1 antibiotics D07CC01 betamethasone and antibiotics - - - 666 4 -1 D07X CORTICOSTEROIDS, OTHER COMBINATIONS - - - 796 2 -2 D07XA Corticosteroids, weak, other combinations - - - 272 0 -10 D07XA01 hydrocortisone - - - 272 0 -10 D07XC Corticosteroids, potent, other combinations - - - 524 3 3 D07XC01 betamethasone, combinations - - - 524 3 3 D08 ANTISEPTICS AND DISINFECTANTS - - - 1 038 70 -4 D08A ANTISEPTICS AND DISINFECTANTS - - - 1 038 70 -4 D08AC Biguanides and amidines - - - 635 99 -6 D08AC02 chlorhexidine - - - 42 90 -53 D08AC52 chlorhexidine, combinations - - - 593 100 0 D08AG Iodine products - - - 402 23 1 D08AG02 povidone-iodine - - - 402 23 1 D09 MEDICATED DRESSINGS - - - 132 19 -6 D09A MEDICATED DRESSINGS - - - 132 19 -6 D09AB Zinc bandages - - - 132 19 -6 D09AB01 zinc bandage without supplements - - - 132 19 -6 D10 ANTI-ACNE PREPARATIONS 1,19 1 4 3 700 1 5 D10A ANTI-ACNE PREPARATIONS FOR TOPICAL - - - 2 343 1 9 USE D10AD Retinoids for topical use in acne - - - 909 2 0 D10AD01 tretinoin - - - 235 1 14 D10AD03 adapalene - - - 167 1 -12 D10AD53 adapalene, combinations - - - 507 3 -1 D10AE Peroxides - - - 461 0 2 D10AE01 benzoyl peroxide - - - 461 0 2 D10AF Antiinfectives for treatment of acne - - - 790 1 30 D10AF01 clindamycin - - - 221 1 1 D10AF51 clindamycin, combinations - - - 570 1 47 Page 24 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

D10AX Other anti-acne preparations for topical use - - - 183 0 3 D10AX03 azelaic acid - - - 183 0 3 D10B ANTI-ACNE PREPARATIONS FOR SYSTEMIC 1,19 1 4 1 356 1 -2 USE D10BA Retinoids for treatment of acne 1,19 1 4 1 356 1 -2 D10BA01 isotretinoin 1,19 1 4 1 356 1 -2 D11 OTHER DERMATOLOGICAL PREPARATIONS 0,11 3 20 5 970 5 42 D11A OTHER DERMATOLOGICAL PREPARATIONS 0,11 3 20 5 970 5 42 D11AC Medicated shampoos - - - 113 0 6 D11AC03 selenium compounds - - - 113 0 6 D11AH Agents for dermatitis, excluding corticosteroids 0,05 7 82 4 325 7 61 D11AH01 tacrolimus - - - 999 2 13 D11AH02 pimecrolimus - - - 438 1 -24 D11AH04 alitretinoin 0,02 0 14 340 0 7 D11AH05 dupilumab 0,03 11 180 2 548 11 183 D11AX Other dermatologicals 0,06 1 -7 1 532 0 8 D11AX01 minoxidil - - - 887 0 14 D11AX10 finasteride 0,06 1 -7 205 1 -3 D11AX16 eflornithine - - - 44 0 -22 D11AX18 diclofenac - - - 5 0 -5 D11AX21 brimonidine - - - 95 0 -15 D11AX22 ivermectin - - - 295 0 18 D11AX24 deoxycholic acid - - - 2 0 -78 G GENITO URINARY SYSTEM AND SEX 180,28 6 2 104 328 6 -7 HORMONES G01 GYNECOLOGICAL ANTIINFECTIVES AND 0,76 1 -5 3 272 1 -5 ANTISEPTICS G01A ANTIINFECTIVES AND ANTISEPTICS, EXCL. 0,76 1 -5 3 272 1 -5 COMBINATIONS WITH CORTICOSTEROIDS G01AA Antibiotics 0,07 1 3 426 0 4 G01AA10 clindamycin 0,07 1 3 426 0 4 G01AC Quinoline derivatives 0,02 0 8 229 0 6 G01AC05 dequalinium 0,02 0 8 229 0 6 G01AF Imidazole derivatives 0,68 1 -6 2 617 1 -7 Page 25 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

G01AF01 metronidazole 0,16 1 -5 769 1 -7 G01AF02 clotrimazole 0,43 1 1 1 724 1 -4 G01AF04 miconazole 0,10 2 -28 124 2 -31 G02 OTHER GYNECOLOGICALS 2,38 12 -14 7 702 39 -6 G02A UTEROTONICS 0,00 100 60 72 100 -5 G02AD Prostaglandins 0,00 100 60 72 100 -5 G02AD02 dinoprostone 0,00 100 86 12 100 86 G02AD06 misoprostol 0,00 100 -13 60 100 -13 G02B CONTRACEPTIVES FOR TOPICAL USE 2,35 12 -14 7 195 35 -7 G02BA Intrauterine contraceptives - - - 5 914 42 -3 G02BA03 plastic IUD with progestogens - - - 5 914 42 -3 G02BB Intravaginal contraceptives 2,35 12 -14 1 280 5 -21 G02BB01 vaginal ring with progestogen and estrogen 2,35 12 -14 1 280 5 -21 G02C OTHER GYNECOLOGICALS 0,03 10 9 435 87 16 G02CB Prolactine inhibitors 0,03 9 10 60 9 11 G02CB01 bromocriptine 0,02 9 8 20 9 8 G02CB03 cabergoline 0,01 9 15 40 9 13 G02CX Other gynecologicals 0,00 99 -32 376 99 16 G02CX01 atosiban 0,00 99 -32 376 99 16 G03 SEX HORMONES AND MODULATORS OF THE 123,28 8 2 56 739 5 -5 GENITAL SYSTEM G03A HORMONAL CONTRACEPTIVES FOR 42,13 22 -2 17 760 15 -5 SYSTEMIC USE G03AA Progestogens and estrogens, fixed combinations 23,57 20 -3 9 633 13 -8 G03AA07 levonorgestrel and ethinylestradiol 0,91 24 50 227 12 34 G03AA09 desogestrel and ethinylestradiol 3,08 18 0 779 4 -12 G03AA10 gestodene and ethinylestradiol 4,62 15 -12 1 173 4 -12 G03AA11 norgestimate and ethinylestradiol 0,00 0 -100 0 0 -100 G03AA12 drospirenone and ethinylestradiol 10,87 21 -7 5 762 15 -11 G03AA13 norelgestromin and ethinylestradiol 0,42 10 -5 253 10 -5 G03AA14 nomegestrol and estradiol 1,30 14 -14 770 14 -11 G03AA16 dienogest and ethinylestradiol 2,37 31 50 669 15 50 G03AB Progestogens and estrogens, sequential 1,58 9 -9 996 9 -9 preparations Page 26 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

G03AB03 levonorgestrel and ethinylestradiol - - -100 0 - -100 G03AB05 desogestrel and ethinylestradiol - - -100 0 - -100 G03AB06 gestodene and ethinylestradiol - - -100 0 - -100 G03AB08 dienogest and estradiol 1,58 9 -9 996 9 -9 G03AC Progestogens 16,95 26 -1 6 173 21 3 G03AC01 norethisterone 0,13 3 -5 165 3 -28 G03AC03 levonorgestrel 0,41 8 -12 267 22 -3 G03AC08 etonogestrel 4,50 59 -4 985 59 -4 G03AC09 desogestrel 11,91 15 0 4 100 12 -8 G03AC10 drospirenone - - - 656 22 - G03AD Emergency contraceptives 0,03 2 -5 958 2 -11 G03AD01 levonorgestrel 0,01 2 -8 464 2 -11 G03AD02 ulipristal 0,02 1 -2 494 2 -11 G03B ANDROGENS 0,63 0 4 5 915 0 2 G03BA 3-oxoandrosten (4) derivatives 0,63 0 4 5 915 0 2 G03BA03 testosterone 0,63 0 4 5 915 0 2 G03C ESTROGENS 65,20 0 6 22 135 1 -6 G03CA Natural and semisynthetic estrogens, plain 64,58 0 6 21 922 1 -6 G03CA03 estradiol 63,97 0 6 18 980 1 -9 G03CA04 estriol 0,61 2 -3 2 942 1 22 G03CC Estrogens, combinations with other drugs - - - 7 0 -51 G03CC07 conjugated estrogens and bazedoxifene - - - 7 0 -51 G03CX Other estrogens 0,62 0 -3 205 1 -7 G03CX01 tibolone 0,62 0 -3 205 1 -7 G03D PROGESTOGENS 2,22 0 -3 1 490 0 2 G03DA Pregnen (4) derivatives 0,53 1 21 427 0 -5 G03DA02 medroxyprogesterone 0,37 1 29 70 1 25 G03DA04 progesterone 0,16 1 6 357 0 -9 G03DB Pregnadien derivatives 0,71 0 31 619 0 26 G03DB01 dydrogesterone 0,58 0 32 317 0 32 G03DB08 dienogest 0,13 0 27 302 0 21 G03DC Estren derivatives 0,98 1 -25 445 1 -15 G03DC02 norethisterone 0,98 1 -11 445 1 -7 G03DC03 lynestrenol - - -100 0 - -100 Page 27 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

G03F PROGESTOGENS AND ESTROGENS IN 10,25 0 0 3 935 0 -7 COMBINATION G03FA Progestogens and estrogens, combinations 7,23 0 2 3 249 0 -6 G03FA01 norethisterone and estrogen 2,27 0 -5 1 085 0 -21 G03FA12 medroxyprogesterone and estrogen 1,15 0 -2 515 0 -2 G03FA14 dydrogesterone and estrogen 3,48 0 12 1 403 0 12 G03FA17 drospirenone and estrogen 0,33 0 -21 246 0 -22 G03FB Progestogens and estrogens, sequential 3,02 0 -4 686 0 -12 preparations G03FB05 norethisterone and estrogen 1,65 0 -8 185 0 -36 G03FB06 medroxyprogesterone and estrogen 0,10 0 -24 21 0 -23 G03FB08 dydrogesterone and estrogen 1,26 0 3 479 0 3 G03G GONADOTROPHINS AND OTHER OVULATION 0,24 0 43 4 303 1 -2 STIMULANTS G03GA Gonadotrophins 0,24 0 43 4 303 1 -2 G03GA01 chorionic gonadotrophin 0,16 0 86 109 0 86 G03GA02 human menopausal gonadotrophin 0,03 0 11 1 327 0 9 G03GA04 urofollitropin 0,00 0 50 38 0 50 G03GA05 follitropin alfa 0,05 2 -4 1 783 2 -4 G03GA06 follitropin beta 0,00 1 -56 13 1 -70 G03GA07 lutropin alfa 0,00 0 -13 1 0 -13 G03GA08 choriogonadotropin alfa 0,00 0 -19 191 0 -19 G03GA09 corifollitropin alfa 0,00 0 -16 177 0 -29 G03GA30 combinations - - - 662 0 -6 G03H ANTIANDROGENS 2,56 3 -17 938 1 -19 G03HA Antiandrogens, plain preparations 0,04 5 -13 103 5 -15 G03HA01 cyproterone 0,04 5 -13 103 5 -15 G03HB Antiandrogens and estrogens 2,51 3 -17 835 1 -19 G03HB01 cyproterone and estrogen 2,51 3 -17 835 1 -19 G03X OTHER SEX HORMONES AND MODULATORS 0,06 9 84 264 73 -18 OF THE GENITAL SYSTEM G03XB Progesterone receptor modulators 0,01 84 -73 203 95 -35 G03XB01 mifepristone 0,01 99 -10 194 99 25 G03XB02 ulipristal 0,00 -3 -94 9 -3 -94 Page 28 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

G03XX Other sex hormones and modulators of the genital 0,05 0 526 61 0 392 system G03XX01 prasterone 0,05 0 526 61 0 392 G04 UROLOGICALS 53,85 2 4 36 615 2 -12 G04B UROLOGICALS 19,65 2 4 19 735 2 -6 G04BD Drugs for urinary frequency and incontinence 7,31 2 2 11 978 3 -3 G04BD04 oxybutynin 0,14 2 -1 202 2 -4 G04BD07 tolterodine 0,24 2 -3 291 3 -6 G04BD08 solifenacin 1,35 2 -10 670 3 -54 G04BD09 trospium 0,18 1 -4 194 1 -6 G04BD10 darifenacin 0,03 2 -21 38 2 -25 G04BD11 fesoterodine 0,44 1 -10 611 2 -15 G04BD12 mirabegron 4,94 2 9 9 971 3 7 G04BE Drugs used in erectile dysfunction 9,06 0 5 6 668 1 -12 G04BE01 alprostadil 0,42 0 30 419 0 -37 G04BE03 sildenafil 7,63 0 1 2 285 2 6 G04BE08 tadalafil 0,99 0 30 3 678 0 -19 G04BE09 vardenafil 0,01 0 -14 76 0 -28 G04BE10 avanafil 0,01 0 -6 56 0 -7 G04BE30 combinations 0,00 1 48 155 1 48 G04BX Other urologicals 3,28 4 5 1 089 4 4 G04BX01 magnesium hydroxide 3,27 4 5 1 042 4 3 G04BX14 dapoxetine 0,01 0 6 47 0 7 G04C DRUGS USED IN BENIGN PROSTATIC 34,20 2 4 16 880 2 -18 HYPERTROPHY G04CA Alpha-adrenoreceptor antagonists 24,79 2 5 11 227 1 -24 G04CA01 alfuzosin 6,08 1 5 1 901 1 -4 G04CA02 tamsulosin 12,07 2 4 3 489 2 0 G04CA52 tamsulosin and dutasteride 6,62 1 7 5 773 1 -37 G04CA53 tamsulosin and solifenacin 0,03 0 -20 64 0 -21 G04CB Testosterone-5-alpha reductase inhibitors 8,85 2 3 5 232 2 -2 G04CB01 finasteride 6,05 2 -2 4 788 2 -2 G04CB02 dutasteride 2,79 2 14 444 2 -9 G04CX Other drugs used in benign prostatic hypertrophy 0,56 0 -12 421 0 -15 Page 29 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

G04CX02 sabalis serrulatae fructus 0,56 0 -12 421 0 -15 H SYSTEMIC HORMONAL PREPARATIONS, 58,92 7 -1 49 703 18 3 EXCL. SEX HORMONES AND INSULINS H01 PITUITARY, HYPOTHALAMIC HORMONES AND 4,07 3 -4 29 256 9 4 ANALOGUES H01A ANTERIOR PITUITARY LOBE HORMONES AND 0,32 1 10 9 957 11 3 ANALOGUES H01AB Thyrotrophin 0,00 100 -10 1 103 100 -10 H01AB01 thyrotrophin alfa 0,00 100 -10 1 103 100 -10 H01AC Somatropin and somatropin agonists 0,31 0 10 8 324 0 5 H01AC01 somatropin 0,31 0 10 8 324 0 5 H01AX Other anterior pituitary hormones and analogues 0,00 0 11 530 0 10 H01AX01 pegvisomant 0,00 0 11 530 0 10 H01B POSTERIOR PITUITARY LOBE HORMONES 3,45 4 -6 2 610 33 -2 H01BA Vasopressin and analogues 3,43 3 -6 2 401 27 -4 H01BA01 vasopressin (argipressin) 0,00 100 59 137 100 61 H01BA02 desmopressin 3,43 3 -6 1 873 6 -8 H01BA04 terlipressin 0,00 100 -8 391 100 6 H01BB Oxytocin and analogues 0,02 100 3 209 100 19 H01BB02 oxytocin 0,02 100 -2 99 100 -21 H01BB03 carbetocin 0,00 100 118 110 100 118 H01C HYPOTHALAMIC HORMONES 0,31 3 6 16 689 4 5 H01CA Gonadotrophin-releasing hormones 0,04 0 14 245 0 14 H01CA02 nafarelin 0,04 0 14 245 0 14 H01CB Somatostatin and analogues 0,25 3 5 16 152 5 5 H01CB02 octreotide 0,12 6 -1 7 430 9 -1 H01CB03 lanreotide 0,13 1 11 8 697 1 11 H01CB05 pasireotide 0,00 40 -44 25 40 -44 H01CC Anti gonadotropin releasing hormones 0,01 1 -4 292 1 -5 H01CC01 ganirelix 0,01 1 -3 278 1 -3 H01CC02 cetrorelix 0,00 0 -29 13 0 -29 H02 CORTICOSTEROIDS FOR SYSTEMIC USE 18,30 18 -5 10 449 54 2 H02A CORTICOSTEROIDS FOR SYSTEMIC USE, 18,22 18 -5 8 378 52 6 PLAIN Page 30 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

H02AA Mineralocorticoids 0,66 7 -3 148 7 -3 H02AA02 fludrocortisone 0,66 7 -3 148 7 -3 H02AB Glucocorticoids 17,56 18 -5 8 230 53 6 H02AB01 betamethasone 0,16 87 2 236 88 1 H02AB02 dexamethasone 2,36 40 7 2 449 58 61 H02AB04 methylprednisolone 1,71 57 5 1 740 74 -2 H02AB06 prednisolone 11,50 7 -8 1 342 14 -16 H02AB07 prednisone 0,55 4 -6 85 4 -6 H02AB08 triamcinolone 0,10 72 5 897 72 5 H02AB09 hydrocortisone 1,18 16 -9 1 482 41 -12 H02B CORTICOSTEROIDS FOR SYSTEMIC USE, 0,09 64 -12 2 070 64 -12 COMBINATIONS H02BX Corticosteroids for systemic use, combinations 0,09 64 -12 2 070 64 -12 H02BX01 methylprednisolone, combinations 0,09 64 -12 2 070 64 -12 H03 THYROID THERAPY 36,28 1 2 6 976 2 1 H03A THYROID PREPARATIONS 35,75 1 2 6 323 2 1 H03AA Thyroid hormones 35,75 1 2 6 323 2 1 H03AA01 levothyroxine sodium 35,75 1 2 6 323 2 1 H03B ANTITHYROID PREPARATIONS 0,54 4 -3 652 4 -3 H03BB Sulphur-containing imidazole derivatives 0,54 4 -3 652 4 -3 H03BB01 carbimazole 0,54 4 -3 652 4 -3 H04 PANCREATIC HORMONES 0,01 65 -15 225 60 -15 H04A GLYCOGENOLYTIC HORMONES 0,01 65 -15 225 60 -15 H04AA Glycogenolytic hormones 0,01 65 -15 225 60 -15 H04AA01 glucagon 0,01 65 -15 225 60 -15 H05 CALCIUM HOMEOSTASIS 0,25 9 2 2 797 11 2 H05A PARATHYROID HORMONES AND ANALOGUES 0,05 7 -7 817 7 -33 H05AA Parathyroid hormones and analogues 0,05 7 -7 817 7 -33 H05AA02 teriparatide 0,05 7 -7 817 7 -33 H05B ANTI-PARATHYROID AGENTS 0,19 10 4 1 981 12 30 H05BA Calcitonin preparations 0,00 98 -53 28 98 -49 H05BA01 calcitonin (salmon synthetic) 0,00 98 -53 28 98 -49 H05BX Other anti-parathyroid agents 0,19 10 4 1 953 11 33 H05BX01 cinacalcet 0,17 6 6 1 779 6 36 Page 31 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

H05BX02 paricalcitol 0,02 46 -7 155 59 14 H05BX04 etelcalcetide 0,00 100 -2 18 100 -2 J ANTIINFECTIVES FOR SYSTEMIC USE 16,75 35 -16 256 848 77 -4 J01 ANTIBACTERIALS FOR SYSTEMIC USE 14,70 33 -17 41 583 58 -7 J01A TETRACYCLINES 2,52 6 -20 1 743 26 -24 J01AA Tetracyclines 2,52 6 -20 1 743 26 -24 J01AA02 doxycycline 1,34 11 -32 728 10 -36 J01AA04 lymecycline 0,82 1 3 469 1 3 J01AA07 tetracycline 0,36 2 -6 185 2 -2 J01AA12 tigecycline 0,00 100 -29 362 100 -29 J01C BETA-LACTAM ANTIBACTERIALS, PENICILLINS 3,65 15 -26 16 723 64 -2 J01CA Penicillins with extended spectrum 1,83 10 -31 4 933 24 -28 J01CA01 ampicillin 0,02 100 -2 870 100 14 J01CA04 amoxicillin 1,20 11 -38 2 612 10 -41 J01CA08 pivmecillinam 0,61 7 -11 1 450 6 -12 J01CE Beta-lactamase sensitive penicillins 1,01 10 -19 1 564 46 -23 J01CE01 benzylpenicillin 0,05 94 -11 723 94 -32 J01CE02 phenoxymethylpenicillin 0,96 6 -19 841 5 -14 J01CF Beta-lactamase resistant penicillins 0,19 52 -6 993 59 -3 J01CF02 cloxacillin 0,08 100 -13 534 100 -7 J01CF05 flucloxacillin 0,10 12 1 459 12 1 J01CR Combinations of penicillins, incl. beta-lactamase 0,62 27 -28 9 233 88 30 inhibitors J01CR02 amoxicillin and beta-lactamase inhibitor 0,53 15 -32 1 291 14 -36 J01CR05 piperacillin and beta-lactamase inhibitor 0,09 100 5 7 942 100 57 J01D OTHER BETA-LACTAM ANTIBACTERIALS 5,06 71 -12 11 181 62 -12 J01DB First-generation cephalosporins 1,56 7 -15 4 379 7 -16 J01DB01 cefalexin 1,56 7 -15 4 365 6 -16 J01DB04 cefazolin 0,00 100 338 13 100 738 J01DC Second-generation cephalosporins 3,37 99 -11 3 157 98 -19 J01DC02 cefuroxime 3,37 99 -11 3 157 98 -19 J01DD Third-generation cephalosporins 0,09 98 16 1 391 95 12 J01DD01 cefotaxime 0,00 100 34 2 100 30 J01DD02 ceftazidime 0,01 100 -4 68 100 -37 Page 32 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

J01DD04 ceftriaxone 0,08 98 17 1 121 94 17 J01DD52 ceftazidime and beta-lactamase inhibitor 0,00 99 12 200 99 12 J01DE Fourth-generation cephalosporins 0,00 100 128 6 100 30 J01DE01 cefepime 0,00 100 128 6 100 30 J01DF Monobactams 0,00 95 -22 32 95 -21 J01DF01 aztreonam 0,00 95 -22 32 95 -21 J01DH Carbapenems 0,04 100 8 1 921 100 -7 J01DH02 meropenem 0,03 100 11 910 100 -13 J01DH03 ertapenem 0,01 100 -2 1 011 100 0 J01DI Other cephalosporins and penems 0,00 100 43 297 100 39 J01DI02 ceftaroline fosamil 0,00 100 53 127 100 53 J01DI54 ceftolozane and beta-lactamase inhibitor 0,00 100 29 170 100 29 J01E SULFONAMIDES AND TRIMETHOPRIM 0,99 8 -12 1 367 8 -11 J01EA Trimethoprim and derivatives 0,70 7 -10 817 6 -7 J01EA01 trimethoprim 0,70 7 -10 817 6 -7 J01EE Combinations of sulfonamides and trimethoprim, 0,29 11 -17 550 11 -17 incl. derivatives J01EE01 sulfamethoxazole and trimethoprim 0,10 14 -3 209 13 15 J01EE02 sulfadiazine and trimethoprim 0,19 10 -23 342 9 -29 J01F MACROLIDES, LINCOSAMIDES AND 0,56 23 -25 2 496 47 -19 STREPTOGRAMINS J01FA Macrolides 0,32 23 -35 1 103 44 -27 J01FA01 erythromycin 0,00 100 23 93 100 22 J01FA06 roxithromycin 0,04 11 -46 100 11 -40 J01FA09 clarithromycin 0,06 29 -38 215 30 -42 J01FA10 azithromycin 0,22 22 -31 694 46 -22 J01FF Lincosamides 0,24 25 -6 1 393 49 -11 J01FF01 clindamycin 0,24 25 -6 1 393 49 -11 J01G AMINOGLYCOSIDE ANTIBACTERIALS 0,01 54 -11 1 076 49 -10 J01GB Other aminoglycosides 0,01 54 -11 1 076 49 -10 J01GB01 tobramycin 0,01 44 -15 725 25 -14 J01GB03 gentamicin 0,00 95 7 119 97 -24 J01GB06 amikacin 0,00 100 19 232 100 21 J01M QUINOLONE ANTIBACTERIALS 0,54 29 -13 2 441 52 -6 Page 33 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

J01MA Fluoroquinolones 0,54 29 -13 2 441 52 -6 J01MA02 ciprofloxacin 0,32 18 -14 1 236 37 -14 J01MA12 levofloxacin 0,18 44 0 808 59 4 J01MA14 moxifloxacin 0,05 47 -36 398 86 3 J01X OTHER ANTIBACTERIALS 1,35 10 -5 4 556 64 3 J01XA Glycopeptide antibacterials 0,03 98 16 1 051 98 -3 J01XA01 vancomycin 0,03 98 17 749 97 -6 J01XA02 teicoplanin 0,00 100 -10 188 100 -3 J01XA04 dalbavancin 0,00 100 27 115 100 27 J01XB Polymyxins 0,00 8 13 177 8 11 J01XB01 colistin 0,00 8 13 177 8 11 J01XC Steroid antibacterials 0,00 10 -88 1 10 -88 J01XC01 fusidic acid 0,00 10 -88 1 10 -88 J01XD Imidazole derivatives 0,05 100 16 1 035 100 50 J01XD01 metronidazole 0,05 100 16 1 035 100 50 J01XE Nitrofuran derivatives 0,31 5 16 558 3 18 J01XE01 nitrofurantoin 0,31 5 16 558 3 18 J01XX Other antibacterials 0,96 4 -11 1 734 47 -14 J01XX01 fosfomycin 0,00 100 -18 9 100 -18 J01XX05 methenamine 0,94 3 -12 840 3 -10 J01XX08 linezolid 0,01 57 -6 434 74 -21 J01XX09 daptomycin 0,00 100 -7 450 100 -12 J02 ANTIMYCOTICS FOR SYSTEMIC USE 0,35 16 -7 13 217 76 -26 J02A ANTIMYCOTICS FOR SYSTEMIC USE 0,35 16 -7 13 217 76 -26 J02AA Antibiotics 0,01 100 -33 1 778 100 -34 J02AA01 amphotericin 0,01 100 -33 1 778 100 -34 J02AB Imidazole derivatives 0,00 0 650 9 0 529 J02AB02 ketoconazole 0,00 0 650 9 0 529 J02AC Triazole derivatives 0,34 12 -6 4 112 25 -13 J02AC01 fluconazole 0,23 14 -8 2 081 14 -17 J02AC02 itraconazole 0,08 2 -6 383 2 1 J02AC03 voriconazole 0,01 23 8 246 56 -63 J02AC04 posaconazole 0,01 39 34 718 45 4 J02AC05 isavuconazole 0,00 25 65 684 38 47 Page 34 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

J02AX Other antimycotics for systemic use 0,01 100 -7 7 318 100 -31 J02AX04 caspofungin 0,00 100 -7 1 848 100 -58 J02AX05 micafungin 0,00 100 -41 2 587 100 -41 J02AX06 anidulafungin 0,00 100 61 2 883 100 61 J04 ANTIMYCOBACTERIALS 0,16 86 -2 767 87 -22 J04A DRUGS FOR TREATMENT OF TUBERCULOSIS 0,16 86 -2 767 87 -22 J04AA Aminosalicylic acid and derivatives 0,00 100 -167 2 100 -167 J04AA01 aminosalicylic acid 0,00 100 -167 2 100 -167 J04AB Antibiotics 0,08 72 -1 370 75 -6 J04AB02 rifampicin 0,07 70 2 305 70 2 J04AB04 rifabutin 0,01 94 -31 64 94 -31 J04AC Hydrazides 0,05 98 0 109 98 12 J04AC01 isoniazid 0,05 98 0 109 98 12 J04AK Other drugs for treatment of tuberculosis 0,04 99 -8 285 99 -42 J04AK01 pyrazinamide 0,01 100 20 85 100 38 J04AK02 ethambutol 0,02 99 -17 154 99 -14 J04AK05 bedaquiline 0,00 100 -82 46 100 -82 J05 ANTIVIRALS FOR SYSTEMIC USE 1,54 53 -4 127 751 94 -9 J05A DIRECT ACTING ANTIVIRALS 1,54 53 -4 127 751 94 -9 J05AB Nucleosides and nucleotides excl. reverse 0,72 8 3 10 495 37 -6 transcriptase inhibitors J05AB01 aciclovir 0,32 4 3 2 873 28 5 J05AB06 ganciclovir 0,00 100 -30 174 100 -31 J05AB09 famciclovir 0,01 8 -2 134 8 -4 J05AB11 valaciclovir 0,36 3 2 4 512 3 -11 J05AB14 valganciclovir 0,03 100 13 2 802 100 -6 J05AE Protease inhibitors 0,03 100 -32 496 100 -74 J05AE01 saquinavir - - -100 0 - -100 J05AE03 ritonavir 0,00 99 -27 104 99 -26 J05AE08 atazanavir 0,01 100 -49 142 100 -68 J05AE10 darunavir 0,02 100 -22 250 100 -80 J05AF Nucleoside and nucleotide reverse transcriptase 0,07 100 2 1 142 100 -11 inhibitors J05AF01 zidovudine - - -100 0 - -100 Page 35 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

J05AF05 lamivudine 0,00 100 -22 50 100 -23 J05AF06 abacavir 0,00 100 -34 45 100 -35 J05AF07 tenofovir disoproxil 0,05 100 8 655 100 -6 J05AF08 adefovir dipivoxil 0,00 100 -17 31 100 -17 J05AF09 emtricitabine 0,00 100 -22 8 100 -22 J05AF10 entecavir 0,01 99 6 117 99 -30 J05AF13 tenofovir alafenamide 0,01 100 3 235 100 3 J05AG Non-nucleoside reverse transcriptase inhibitors 0,04 100 5 761 100 -14 J05AG01 nevirapine 0,02 100 -11 207 100 -56 J05AG03 efavirenz 0,01 100 22 115 100 41 J05AG04 etravirine 0,00 100 -49 83 100 -49 J05AG05 rilpivirine 0,01 100 17 133 100 14 J05AG06 doravirine 0,01 100 334 223 100 334 J05AH Neuraminidase inhibitors 0,04 15 -51 358 14 -54 J05AH02 oseltamivir 0,04 15 -51 358 14 -54 J05AJ Integrase inhibitors 0,19 100 2 7 045 100 -2 J05AJ01 raltegravir 0,07 100 0 2 179 100 -2 J05AJ03 dolutegravir 0,12 100 3 4 866 100 -2 J05AP Antivirals for treatment of HCV infections 0,07 100 -5 84 527 100 -6 J05AP01 ribavirin 0,00 99 -85 42 99 -85 J05AP08 sofosbuvir 0,00 100 200 126 100 200 J05AP51 sofosbuvir and ledipasvir 0,00 100 633 361 100 633 J05AP54 elbasvir and grazoprevir 0,01 100 -63 4 388 100 -74 J05AP55 sofosbuvir and velpatasvir 0,05 100 -8 58 351 100 -8 J05AP56 sofosbuvir, velpatasvir and voxilaprevir 0,00 100 458 1 205 100 458 J05AP57 glecaprevir and pibrentasvir 0,02 100 118 20 054 100 118 J05AR Antivirals for treatment of HIV infections, 0,37 94 -8 21 672 100 -17 combinations J05AR01 zidovudine and lamivudine 0,00 100 -59 12 100 -60 J05AR02 lamivudine and abacavir 0,03 99 -2 155 99 -61 J05AR03 tenofovir disoproxil and emtricitabine 0,13 82 41 1 215 94 -47 J05AR04 zidovudine, lamivudine and abacavir - - -100 0 - -100 J05AR06 emtricitabine, tenofovir disoproxil and efavirenz 0,01 96 -52 194 97 -74 J05AR08 emtricitabine, tenofovir disoproxil and rilpivirine 0,00 100 -31 137 100 -31 Page 36 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

J05AR09 emtricitabine, tenofovir disoproxil, elvitegravir and 0,00 100 -37 96 100 -38 cobicistat J05AR10 lopinavir and ritonavir 0,00 98 -68 27 98 -66 J05AR13 lamivudine, abacavir and dolutegravir 0,08 100 -19 6 124 100 -17 J05AR14 darunavir and cobicistat 0,01 100 13 242 100 11 J05AR17 emtricitabine and tenofovir alafenamide 0,07 100 -29 2 651 100 -30 J05AR18 emtricitabine, tenofovir alafenamide, elvitegravir 0,01 100 -25 1 092 100 -23 and cobicistat J05AR19 emtricitabine, tenofovir alafenamide and rilpivirine 0,02 100 -26 1 420 100 -25 J05AR20 emtricitabine, tenofovir alafenamide and bictegravir - - - 4 632 100 -14 J05AR21 dolutegravir and rilpivirine - - - 215 100 18 J05AR22 emtricitabine, tenofovir alafenamide, darunavir 0,02 100 -1 1 010 100 -31 and cobicistat J05AR24 lamivudine, tenofovir disoproxil and doravirine - - - 1 901 100 317 J05AR25 lamivudine and dolutegravir - - - 549 100 640 J05AX Other antivirals 0,00 74 75 1 256 65 157 J05AX09 maraviroc 0,00 98 -4 82 97 -1 J05AX18 letermovir 0,00 61 208 1 173 62 190 J06 IMMUNE SERA AND IMMUNOGLOBULINS - - - 51 951 80 21 J06B IMMUNOGLOBULINS - - - 51 951 80 21 J06BA Immunoglobulins, normal human - - - 50 570 80 22 J06BA01 immunoglobulins, normal human, for extravascular - - - 10 595 3 20 adm. J06BA02 immunoglobulins, normal human, for intravascular - - - 39 974 100 22 adm. J06BB Specific immunoglobulins - - - 1 381 100 -14 J06BB01 anti-D (rh) immunoglobulin - - - 645 100 5 J06BB16 palivizumab - - - 550 100 -31 J06BB21 bezlotoxumab - - - 186 100 -9 J07 VACCINES - - - 21 579 9 2 J07A BACTERIAL VACCINES - - - 9 670 17 95 J07AE Cholera vaccines - - - 50 28 -60 J07AE01 cholera, inactivated, whole cell - - - 50 28 -60 J07AG Haemophilus influenzae B vaccines - - - 19 96 -9 Page 37 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

J07AG01 haemophilus influenzae B, purified antigen - - - 19 96 -9 conjugated J07AH Meningococcal vaccines - - - 1 212 96 0 J07AH08 meningococcus A, C, Y, W-135, tetravalent - - - 1 178 96 -2 purified polysaccharides antigen conjugated J07AH09 meningococcus B, multicomponent vaccine - - - 34 84 162 J07AJ Pertussis vaccines - - - 93 1 8 J07AJ52 pertussis, purified antigen, combinations with - - - 93 1 8 toxoids J07AL Pneumococcal vaccines - - - 7 967 5 164 J07AL01 pneumococcus, purified polysaccharides antigen - - - 96 13 -34 J07AL02 pneumococcus, purified polysaccharides antigen - - - 7 871 5 174 conjugated J07AM Tetanus vaccines - - - 258 2 1 J07AM51 tetanus toxoid, combinations with diphtheria toxoid - - - 258 2 1 J07AP Typhoid vaccines - - - 72 23 -71 J07AP01 typhoid, oral, live attenuated - - - 29 5 -75 J07AP03 typhoid, purified polysaccharide antigen - - - 44 35 -67 J07B VIRAL VACCINES - - - 11 886 3 -26 J07BA Encephalitis vaccines - - - 4 201 1 -13 J07BA01 encephalitis, tick borne, inactivated, whole virus - - - 4 061 1 -10 J07BA02 encephalitis, Japanese, inactivated, whole virus - - - 141 1 -52 J07BB Influenza vaccines - - - 3 424 1 16 J07BB02 influenza, purified antigen - - - 3 286 1 15 J07BB03 influenza, live attenuated - - - 138 1 87 J07BC Hepatitis vaccines - - - 3 455 6 -53 J07BC01 hepatitis B, purified antigen - - - 606 17 -40 J07BC02 hepatitis A, inactivated, whole virus - - - 456 3 -52 J07BC20 combinations - - - 2 393 3 -55 J07BD Measles vaccines - - - 69 0 -33 J07BD52 measles, combinations with mumps and rubella, - - - 69 0 -33 live attenuated J07BF Poliomyelitis vaccines - - - 24 17 -31 J07BF03 poliomyelitis, trivalent, inactivated, whole virus - - - 24 17 -31 Page 38 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

J07BH Rota virus diarrhea vaccines - - - 5 16 1 J07BH02 rota virus, pentavalent, live, reassorted - - - 5 16 1 J07BK Varicella zoster vaccines - - - 335 2 -5 J07BK01 varicella, live attenuated - - - 96 6 -40 J07BK02 zoster, live attenuated - - - 239 1 25 J07BL Yellow fever vaccines - - - 116 9 -65 J07BL01 yellow fever, live attenuated - - - 116 9 -65 J07BM Papillomavirus vaccines - - - 257 8 -13 J07BM02 papillomavirus (human types 16, 18) - - - 0 - - J07BM03 ppapillomavirus (human types 6, 11, 16, 18, 31, - - - 257 8 -13 33, 45, 52, 58) J07C BACTERIAL AND VIRAL VACCINES, COMBINED - - - 23 0 -39 J07CA Bacterial and viral vaccines, combined - - - 23 0 -39 J07CA02 diphtheria, pertussis, poliomyelitis, tetanus - - - 11 0 62 J07CA06 diphtheria, Haemophilus influenzae B, pertussis, - - - 6 0 -11 poliomyelitis, tetanus J07CA10 typhoid - hepatitis A - - - 6 0 -76 L ANTINEOPLASTIC AND 23,08 13 4 813 993 42 4 IMMUNOMODULATING AGENTS L01 ANTINEOPLASTIC AGENTS - - - 328 313 68 6 L01A ALKYLATING AGENTS - - - 6 217 73 2 L01AA Nitrogen mustard analogues - - - 2 805 95 5 L01AA01 cyclophosphamide - - - 712 96 -5 L01AA02 chlorambucil - - - 96 14 -15 L01AA03 melphalan - - - 457 93 603 L01AA05 chlormethine - - - 10 100 - L01AA06 ifosfamide - - - 451 100 -10 L01AA09 bendamustine - - - 1 080 100 -13 L01AB Alkyl sulphonates - - - 646 100 189 L01AB01 busulfan - - - 120 100 11 L01AB02 treosulfan - - - 525 100 355 L01AC Ethylene imines - - - 460 100 -14 L01AC01 thiotepa - - - 460 100 -14 L01AD Nitrosoureas - - - 634 99 -19 Page 39 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

L01AD01 carmustine - - - 547 100 -23 L01AD02 lomustine - - - 29 85 52 L01AD04 streptozocin - - - 57 100 13 L01AX Other alkylating agents - - - 1 672 8 -12 L01AX03 temozolomide - - - 1 603 4 -11 L01AX04 dacarbazine - - - 69 100 -29 L01B ANTIMETABOLITES - - - 17 391 82 -2 L01BA Folic acid analogues - - - 6 349 98 -1 L01BA01 methotrexate - - - 421 70 -11 L01BA04 pemetrexed - - - 5 928 100 0 L01BB Purine analogues - - - 537 39 -17 L01BB02 mercaptopurine - - - 299 6 19 L01BB04 cladribine - - - 94 100 52 L01BB05 fludarabine - - - 103 57 -42 L01BB06 clofarabine - - - 38 100 -68 L01BB07 nelarabine - - - 4 100 -89 L01BC Pyrimidine analogues - - - 10 505 74 -1 L01BC01 cytarabine - - - 156 100 60 L01BC02 fluorouracil - - - 403 100 12 L01BC05 gemcitabine - - - 531 100 -47 L01BC06 capecitabine - - - 955 2 -17 L01BC07 azacitidine - - - 6 417 100 1 L01BC08 decitabine - - - 216 100 -44 L01BC52 fluorouracil, combinations - - - 6 0 245 L01BC53 tegafur, combinations - - - 100 9 -21 L01BC59 trifluridine, combinations - - - 1 720 1 53 L01C PLANT ALKALOIDS AND OTHER NATURAL - - - 13 972 94 -5 PRODUCTS L01CA Vinca alkaloids and analogues - - - 1 187 52 -36 L01CA01 vinblastine - - - 36 96 32 L01CA02 vincristine - - - 177 99 69 L01CA04 vinorelbine - - - 810 31 -48 L01CA05 vinflunine - - - 165 100 14 L01CB Podophyllotoxin derivatives - - - 452 76 29 Page 40 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

L01CB01 etoposide - - - 452 76 29 L01CD Taxanes - - - 11 102 100 1 L01CD01 paclitaxel - - - 6 198 100 15 L01CD02 docetaxel - - - 739 100 -20 L01CD04 cabazitaxel - - - 4 165 100 -11 L01CE Topoisomerase 1 (TOP1) inhibitors - - - 700 85 -26 L01CE01 topotecan - - - 185 45 -22 L01CE02 irinotecan - - - 515 100 -28 L01CX Other plant alkaloids and other natural products - - - 530 100 -9 L01CX01 trabectedin - - - 530 100 -9 L01D CYTOTOXIC ANTIBIOTICS AND RELATED - - - 2 566 99 -21 SUBSTANCES L01DB Anthracyclines and related substances - - - 2 176 100 -19 L01DB01 doxorubicin - - - 1 488 100 -16 L01DB03 epirubicin - - - 275 100 -44 L01DB06 idarubicin - - - 268 100 4 L01DB07 mitoxantrone - - - 113 100 15 L01DB11 pixantrone - - - 32 100 -52 L01DC Other cytotoxic antibiotics - - - 390 98 -31 L01DC01 bleomycin - - - 102 100 25 L01DC03 mitomycin - - - 287 97 -40 L01E PROTEIN KINASE INHIBITORS - - - 91 282 4 10 L01EA BCR-ABL tyrosine kinase inhibitors - - - 10 865 3 -9 L01EA01 imatinib - - - 4 913 0 -11 L01EA02 dasatinib - - - 2 174 6 -21 L01EA03 nilotinib - - - 2 576 1 1 L01EA04 bosutinib - - - 342 0 17 L01EA05 ponatinib - - - 860 20 1 L01EB Epidermal growth factor receptor (EGFR) tyrosine - - - 5 257 1 8 kinase inhibitors L01EB01 gefitinib - - - 232 1 -63 L01EB02 erlotinib - - - 553 3 -44 L01EB03 afatinib - - - 1 806 1 4 L01EB04 osimertinib - - - 2 666 1 74 Page 41 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

L01EC B-Raf serine-threonine kinase (BRAF) inhibitors - - - 5 820 1 -8 L01EC01 vemurafenib - - - 225 1 -44 L01EC02 dabrafenib - - - 4 694 1 -17 L01EC03 encorafenib - - - 900 0 262 L01ED Anaplastic lymphoma kinase (ALK) inhibitors - - - 3 592 7 34 L01ED01 crizotinib - - - 1 169 4 -20 L01ED03 alectinib - - - 2 061 2 76 L01ED04 brigatinib - - - 223 68 363 L01ED05 lorlatinib - - - 139 0 - L01EE Mitogen-activated protein kinase (MEK) inhibitors - - - 3 695 1 17 L01EE01 trametinib - - - 2 892 1 -2 L01EE03 binimetinib - - - 803 1 250 L01EF Cyclin-dependent kinase (CDK) inhibitors - - - 14 586 0 32 L01EF01 palbociclib - - - 14 439 0 31 L01EF02 ribociclib - - - 76 0 100 L01EF03 abemaciclib - - - 72 3 - L01EG Mammalian target of rapamycin (mTOR) kinase - - - 1 609 8 0 inhibitors L01EG01 temsirolimus - - - 61 100 5 L01EG02 everolimus - - - 1 548 5 0 L01EH Human epidermal growth factor receptor 2 (HER2) - - - 436 3 -19 tyrosine kinase inhibitors L01EH01 lapatinib - - - 436 3 -19 L01EJ Janus-associated kinase (JAK) inhibitors - - - 5 631 17 19 L01EJ01 ruxolitinib - - - 5 631 17 19 L01EK Vascular endothelial growth factor receptor - - - 911 0 -17 (VEGFR) tyrosine kinase inhibitors L01EK01 axitinib - - - 911 0 -17 L01EL Bruton's tyrosine kinase (BTK) inhibitors - - - 12 908 1 25 L01EL01 ibrutinib - - - 12 908 1 25 L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors - - - 1 024 1 -31 L01EM01 idelalisib - - - 1 024 1 -31 L01EX Other protein kinase inhibitors - - - 24 947 6 9 L01EX01 sunitinib - - - 3 792 1 -32 Page 42 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

L01EX02 sorafenib - - - 1 880 14 0 L01EX03 pazopanib - - - 2 045 2 -15 L01EX04 vandetanib - - - 30 100 -73 L01EX05 regorafenib - - - 926 0 -19 L01EX07 cabozantinib - - - 8 588 2 35 L01EX08 lenvatinib - - - 1 106 4 104 L01EX09 nintedanib - - - 4 562 1 19 L01EX10 midostaurin - - - 1 813 44 76 L01EX12 larotrectinib - - - 86 85 - L01EX13 gilteritinib - - - 119 14 - L01X OTHER ANTINEOPLASTIC AGENTS - - - 196 886 94 7 L01XA Platinum compounds - - - 1 319 100 21 L01XA01 cisplatin - - - 273 100 10 L01XA02 carboplatin - - - 469 100 40 L01XA03 oxaliplatin - - - 577 100 15 L01XC Monoclonal antibodies - - - 162 695 100 6 L01XC02 rituximab - - - 28 912 100 -19 L01XC03 trastuzumab - - - 30 979 100 11 L01XC05 gemtuzumab ozogamicin - - - 137 100 36 L01XC06 cetuximab - - - 2 104 100 -31 L01XC07 bevacizumab - - - 25 984 100 2 L01XC08 panitumumab - - - 4 775 100 4 L01XC10 ofatumumab - - - 0 - -100 L01XC11 ipilimumab - - - 1 240 100 48 L01XC12 brentuximab vedotin - - - 1 160 100 9 L01XC13 pertuzumab - - - 12 253 100 12 L01XC14 trastuzumab emtansine - - - 5 676 100 19 L01XC15 obinutuzumab - - - 1 461 100 -14 L01XC17 nivolumab - - - 12 347 100 12 L01XC18 pembrolizumab - - - 22 396 100 52 L01XC19 blinatumomab - - - 1 156 100 -44 L01XC21 ramucirumab - - - 551 100 34 L01XC23 elotuzumab - - - 42 100 -79 L01XC24 daratumumab - - - 6 187 100 9 Page 43 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

L01XC26 inotuzumab ozogamicin - - - 399 100 29 L01XC27 olaratumab - - - 0 - -100 L01XC28 durvalumab - - - 863 100 149 L01XC31 avelumab - - - 2 0 -97 L01XC32 atezolizumab - - - 3 894 100 50 L01XC33 cemiplimab - - - 109 100 375 L01XC37 polatuzumab vedotin - - - 66 100 - L01XD Sensitizers used in photodynamic/radiation therapy - - - 1 051 99 5 L01XD03 methyl aminolevulinate - - - 820 99 9 L01XD04 aminolevulinic acid - - - 231 100 -9 L01XF Retinoids for cancer treatment - - - 391 100 1 L01XF01 tretinoin - - - 32 99 3 L01XF03 bexarotene - - - 359 100 1 L01XG Proteasome inhibitors - - - 17 723 88 -10 L01XG01 bortezomib - - - 8 001 100 -22 L01XG02 carfilzomib - - - 7 531 100 2 L01XG03 ixazomib - - - 2 190 3 3 L01XJ Hedgehog pathway inhibitors - - - 319 4 9 L01XJ01 vismodegib - - - 319 4 9 L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors - - - 4 683 0 158 L01XK01 olaparib - - - 2 249 1 49 L01XK02 niraparib - - - 2 433 0 710 L01XX Other antineoplastic agents - - - 8 340 52 42 L01XX05 hydroxycarbamide - - - 533 2 8 L01XX11 estramustine - - - 1 19 -55 L01XX23 mitotane - - - 197 4 11 L01XX24 pegaspargase - - - 622 100 28 L01XX27 arsenic trioxide - - - 298 100 -13 L01XX35 anagrelide - - - 351 1 -11 L01XX41 eribulin - - - 1 358 100 26 L01XX44 aflibercept - - - 295 100 -22 L01XX51 talimogene laherparepvec - - - 347 100 535 L01XX52 venetoclax - - - 4 338 32 75 L01XY Combinations of antineoplastic agents - - - 366 100 72 Page 44 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

L01XY01 cytarabine and daunorubicin - - - 366 100 72 L02 ENDOCRINE THERAPY 6,64 3 -1 70 383 2 8 L02A HORMONES AND RELATED AGENTS 0,74 3 7 12 168 5 0 L02AB Progestogens 0,01 8 -5 89 8 -5 L02AB02 medroxyprogesterone 0,01 8 -5 89 8 -5 L02AE Gonadotrophin releasing hormone analogues 0,73 3 7 12 079 5 0 L02AE01 buserelin - - -100 0 - -100 L02AE02 leuprorelin 0,20 5 -3 8 531 6 -3 L02AE03 goserelin 0,18 4 -8 1 213 4 -10 L02AE04 triptorelin 0,35 2 25 2 335 2 23 L02B HORMONE ANTAGONISTS AND RELATED 5,90 3 -2 58 215 2 10 AGENTS L02BA Anti-estrogens 1,20 2 -2 3 661 7 3 L02BA01 tamoxifen 1,02 1 -3 515 1 -6 L02BA02 toremifene 0,00 1 -35 7 1 -35 L02BA03 fulvestrant 0,17 7 5 3 138 8 5 L02BB Anti-androgens 1,56 2 -7 34 846 1 8 L02BB01 flutamide 0,00 4 -41 16 4 -41 L02BB03 bicalutamide 1,39 3 -8 1 949 3 49 L02BB04 enzalutamide 0,16 1 9 32 729 1 5 L02BB05 apalutamid 0,00 2 - 114 2 - L02BB06 darolutamide - - - 38 0 - L02BG Aromatase inhibitors 2,78 1 -2 2 882 2 5 L02BG03 anastrozole 0,24 2 -18 278 3 -16 L02BG04 letrozole 2,26 1 -1 2 031 1 2 L02BG06 exemestane 0,28 2 8 573 3 29 L02BX Other hormone antagonists and related agents 0,36 21 14 16 825 3 18 L02BX02 degarelix 0,29 26 13 2 138 19 10 L02BX03 abiraterone 0,07 1 19 14 688 1 19 L03 IMMUNOSTIMULANTS 0,68 7 -4 31 137 16 -2 L03A IMMUNOSTIMULANTS 0,68 7 -4 31 137 16 -2 L03AA Colony stimulating factors 0,29 13 20 16 115 15 3 L03AA02 filgrastim 0,04 25 23 2 704 33 4 L03AA10 lenograstim 0,00 23 58 29 23 58 Page 45 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

L03AA13 pegfilgrastim 0,18 15 22 9 916 15 7 L03AA14 lipegfilgrastim 0,07 1 12 3 467 1 -8 L03AB Interferons 0,29 3 -19 7 863 8 -13 L03AB04 interferon alfa-2a - - -100 0 - -100 L03AB05 interferon alfa-2b - - -100 0 - -100 L03AB07 interferon beta-1a 0,22 0 -16 4 793 0 -16 L03AB08 interferon beta-1b 0,02 0 -16 713 0 -10 L03AB11 peginterferon alfa-2a 0,01 99 316 607 99 319 L03AB13 peginterferon beta-1a 0,04 0 7 1 712 0 4 L03AB15 ropeginterferon alfa-2b - - - 37 100 - L03AX Other immunostimulants 0,10 0 -5 7 159 27 0 L03AX03 BCG vaccine - - - 918 100 46 L03AX13 glatiramer acetate 0,10 0 -5 5 213 0 -8 L03AX16 plerixafor 0,00 100 25 1 028 100 25 L04 IMMUNOSUPPRESSANTS 15,77 17 6 384 159 30 2 L04A IMMUNOSUPPRESSANTS 15,77 17 6 384 159 30 2 L04AA Selective immunosuppressants 2,04 19 9 90 197 45 10 L04AA04 antithymocyte immunoglobulin 0,00 100 -37 104 100 -37 L04AA06 mycophenolic acid 0,49 3 5 4 839 4 2 L04AA10 sirolimus 0,01 15 1 193 15 1 L04AA13 leflunomide 0,56 1 5 611 1 47 L04AA18 everolimus 0,00 97 10 172 97 10 L04AA23 natalizumab 0,05 100 3 7 738 100 4 L04AA24 abatacept 0,09 36 2 7 512 34 1 L04AA26 belimumab 0,01 100 16 478 100 16 L04AA27 fingolimod 0,12 0 -7 12 807 0 -8 L04AA28 belatacept 0,00 100 - 5 100 - L04AA29 tofacitinib 0,10 1 10 5 574 1 7 L04AA31 teriflunomide 0,15 0 9 7 721 0 4 L04AA32 apremilast 0,07 0 29 3 601 0 27 L04AA33 vedolizumab 0,21 100 18 20 271 100 6 L04AA34 alemtuzumab 0,00 100 -81 83 100 -81 L04AA36 ocrelizumab 0,06 100 67 8 537 100 67 L04AA37 baricitinib 0,07 1 12 4 477 1 11 Page 46 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

L04AA40 cladribine 0,04 0 75 5 240 0 71 L04AA44 upadacitinib - - - 235 0 - L04AB Tumor necrosis factor alpha (TNF-a) inhibitors 4,20 47 9 163 610 39 -8 L04AB01 etanercept 0,55 0 5 24 182 0 3 L04AB02 infliximab 1,94 100 14 63 663 100 -16 L04AB04 adalimumab 1,07 1 7 47 071 1 -6 L04AB05 certolizumab pegol 0,12 0 -2 6 606 0 -4 L04AB06 golimumab 0,53 1 6 22 088 1 2 L04AC Interleukin inhibitors 1,04 22 28 48 846 18 20 L04AC02 basiliximab 0,00 100 9 386 100 10 L04AC03 anakinra 0,01 9 17 539 9 16 L04AC05 ustekinumab 0,56 31 41 17 729 25 31 L04AC07 tocilizumab 0,14 38 -8 7 892 47 -13 L04AC08 canakinumab 0,00 100 - 156 100 - L04AC10 secukinumab 0,15 0 0 9 749 0 -1 L04AC11 siltuximab - - -100 0 - -100 L04AC12 brodalumab 0,00 0 57 205 0 54 L04AC13 ixekizumab 0,08 1 30 4 870 1 29 L04AC14 sarilumab 0,02 0 52 1 081 0 48 L04AC16 guselkumab 0,07 1 72 4 655 1 71 L04AC18 risankizumab 0,03 0 19 400 1 584 0 19 400 L04AD Calcineurin inhibitors 0,79 4 2 11 799 5 -3 L04AD01 ciclosporin 0,36 4 -6 4 418 4 -7 L04AD02 tacrolimus 0,42 5 9 7 380 5 0 L04AX Other immunosuppressants 7,69 1 2 69 707 2 8 L04AX01 azathioprine 1,22 0 5 919 0 7 L04AX02 thalidomide 0,00 25 -7 72 25 -7 L04AX03 methotrexate 6,10 1 1 9 591 1 15 L04AX04 lenalidomide 0,10 3 1 31 671 3 5 L04AX05 pirfenidone 0,04 1 10 6 083 1 8 L04AX06 pomalidomide 0,01 1 30 8 259 1 28 L04AX07 dimethyl fumarate 0,22 0 9 13 112 0 -1 M MUSCULO-SKELETAL SYSTEM 98,64 2 -3 97 783 20 -4 M01 ANTIINFLAMMATORY AND ANTIRHEUMATIC 77,57 2 -4 42 960 2 -7 PRODUCTS Page 47 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

M01A ANTIINFLAMMATORY AND ANTIRHEUMATIC 77,57 2 -4 42 751 2 -7 PRODUCTS, NON-STEROIDS M01AB Acetic acid derivatives and related substances 3,75 2 -4 2 120 6 -6 M01AB01 indometacin 0,18 1 3 138 1 8 M01AB05 diclofenac 3,51 2 -5 1 862 4 -6 M01AB15 ketorolac 0,02 84 -2 49 84 -6 M01AB55 diclofenac, combinations 0,05 0 -15 71 0 -15 M01AC Oxicams 1,03 2 -8 339 2 -7 M01AC06 meloxicam 1,03 2 -8 339 2 -7 M01AE Propionic acid derivatives 58,28 2 -5 32 592 2 -6 M01AE01 ibuprofen 50,07 2 -5 29 032 1 -5 M01AE02 naproxen 5,60 2 -6 1 405 2 -15 M01AE03 ketoprofen 0,60 1 -9 421 1 -9 M01AE17 dexketoprofen 0,05 63 8 162 82 -19 M01AE51 ibuprofen, combinations 0,46 0 -18 693 0 -20 M01AE52 naproxen and esomeprazole 1,49 0 -1 878 0 -1 M01AG Fenamates 0,19 3 -9 84 4 -9 M01AG01 mefenamic acid 0,03 13 -9 16 18 -8 M01AG02 tolfenamic acid 0,16 0 -9 68 0 -9 M01AH Coxibs 11,43 1 7 3 238 3 -14 M01AH01 celecoxib 0,61 3 -5 178 2 -17 M01AH04 parecoxib 0,00 99 3 51 99 3 M01AH05 etoricoxib 10,82 1 8 3 009 1 -14 M01AX Other antiinflammatory and antirheumatic agents, 2,88 1 -14 4 378 0 -8 non-steroids M01AX01 nabumetone 0,02 1 -45 8 1 -42 M01AX05 glucosamine 2,87 1 -13 1 802 1 -12 M01AX25 chondroitin sulfate - - - 2 568 0 -4 M01C SPECIFIC ANTIRHEUMATIC AGENTS - - -100 209 0 51 M01CB Gold preparations - - -100 0 - -100 M01CB01 sodium aurothiomalate - - -100 0 - -100 M01CX Other specific antirheumatic agents - - - 209 0 98 M02 TOPICAL PRODUCTS FOR JOINT AND - - - 14 134 1 9 MUSCULAR PAIN Page 48 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

M02A TOPICAL PRODUCTS FOR JOINT AND - - - 14 134 1 9 MUSCULAR PAIN M02AA Antiinflammatory preparations, non-steroids for - - - 13 260 1 10 topical use M02AA07 piroxicam - - - 881 2 2 M02AA10 ketoprofen - - - 96 23 -2 M02AA13 ibuprofen - - - 761 0 -32 M02AA15 diclofenac - - - 11 523 0 16 M02AC Preparations with salicylic acid derivatives - - - 873 5 -4 M03 MUSCLE RELAXANTS 5,15 2 -2 14 652 62 -4 M03A MUSCLE RELAXANTS, PERIPHERALLY - - - 9 753 76 -4 ACTING AGENTS M03AB Choline derivatives - - - 639 99 28 M03AB01 suxamethonium - - - 639 99 28 M03AC Other quaternary ammonium compounds - - - 1 083 99 -42 M03AC09 rocuronium bromide - - - 915 99 -48 M03AC10 mivacurium chloride - - - 14 87 -35 M03AC11 cisatracurium - - - 154 100 93 M03AX Other muscle relaxants, peripherally acting agents - - - 8 031 72 3 M03AX01 botulinum toxin - - - 8 031 72 3 M03B MUSCLE RELAXANTS, CENTRALLY ACTING 5,15 2 -2 4 899 32 -3 AGENTS M03BC Ethers, chemically close to antihistamines 2,76 1 -2 1 143 37 -8 M03BC01 orphenadrine (citrate) 2,52 1 0 1 026 42 -7 M03BC51 orphenadrine, combinations 0,24 0 -22 117 0 -20 M03BX Other centrally acting agents 2,39 3 -2 3 756 31 -2 M03BX01 baclofen 0,53 9 -3 1 617 69 -2 M03BX02 tizanidine 1,86 2 -1 2 138 2 -2 M04 ANTIGOUT PREPARATIONS 4,46 2 7 1 791 2 -8 M04A ANTIGOUT PREPARATIONS 4,46 2 7 1 791 2 -8 M04AA Preparations inhibiting uric acid production 4,44 2 7 1 739 2 -8 M04AA01 allopurinol 4,15 2 6 1 493 2 -5 M04AA03 febuxostat 0,29 3 12 246 3 -25 M04AC Preparations with no effect on uric acid metabolism 0,02 12 22 52 12 22 Page 49 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

M04AC01 colchicine 0,02 12 22 52 12 22 M05 DRUGS FOR TREATMENT OF BONE DISEASES 11,45 5 1 16 916 15 2 M05B DRUGS AFFECTING BONE STRUCTURE AND 11,45 5 1 16 916 15 2 MINERALIZATION M05BA Bisphosphonates 3,19 2 -4 3 199 54 18 M05BA02 clodronic acid 0,01 1 -29 86 2 -32 M05BA03 pamidronic acid 0,00 100 -26 43 100 -16 M05BA04 alendronic acid 2,27 2 -2 895 2 -6 M05BA06 ibandronic acid 0,36 2 -11 168 3 -17 M05BA07 risedronic acid 0,54 3 -8 335 3 -6 M05BA08 zoledronic acid 0,00 100 -49 1 672 99 64 M05BB Bisphosphonates, combinations 0,20 2 -12 121 2 -13 M05BB03 alendronic acid and colecalciferol 0,20 2 -12 121 2 -13 M05BC Bone morphogenetic proteins - - - 46 100 -17 M05BC01 dibotermin alfa - - - 46 100 -17 M05BX Other drugs affecting mineralization 8,06 6 4 13 550 6 0 M05BX04 denosumab 8,06 6 4 13 550 6 0 M09 OTHER DRUGS FOR DISORDERS OF THE 0,02 43 -59 7 330 98 -24 MUSCULO-SKELETAL SYSTEM M09A OTHER DRUGS FOR DISORDERS OF THE 0,02 43 -59 7 330 98 -24 MUSCULO-SKELETAL SYSTEM M09AB Enzymes 0,00 100 -99 9 100 -99 M09AB02 collagenase clostridium histolyticum 0,00 100 -99 9 100 -99 M09AX Other drugs for disorders of the musculo-skeletal 0,02 43 -58 7 321 98 -13 system M09AX01 hyaluronic acid 0,02 26 -64 154 26 -63 M09AX07 nusinersen 0,01 100 -10 7 166 100 -10 N NERVOUS SYSTEM 326,60 14 6 385 113 30 7 N01 ANESTHETICS - - - 17 632 88 -8 N01A ANESTHETICS, GENERAL - - - 8 599 96 -12 N01AB Halogenated hydrocarbons - - - 2 386 98 -13 N01AB06 isoflurane - - - 12 100 -11 N01AB07 desflurane - - - 390 100 -34 N01AB08 sevoflurane - - - 1 984 97 -7 Page 50 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

N01AF Barbiturates, plain - - - 50 99 85 N01AF03 thiopental - - - 50 99 85 N01AH Opioid anesthetics - - - 1 710 94 9 N01AH01 fentanyl - - - 235 99 0 N01AH02 alfentanil - - - 139 88 -16 N01AH03 sufentanil - - - 30 100 -15 N01AH06 remifentanil - - - 1 305 94 16 N01AX Other general anesthetics - - - 4 453 96 -19 N01AX03 ketamine - - - 26 89 -51 N01AX10 propofol - - - 3 338 96 -17 N01AX14 esketamine - - - 1 089 99 -23 N01B ANESTHETICS, LOCAL - - - 9 033 80 -4 N01BB Amides - - - 8 573 79 -4 N01BB01 bupivacaine - - - 617 97 -22 N01BB02 lidocaine - - - 1 790 77 -3 N01BB03 mepivacaine - - - 5 11 -1 N01BB04 prilocaine - - - 1 82 - N01BB09 ropivacaine - - - 1 561 97 1 N01BB10 levobupivacaine - - - 975 98 -3 N01BB20 combinations - - - 1 036 45 -6 N01BB51 bupivacaine, combinations - - - 24 92 -45 N01BB52 lidocaine, combinations - - - 1 219 81 9 N01BB54 prilocaine, combinations - - - 149 62 26 N01BB58 articaine, combinations - - - 1 196 66 -12 N01BX Other local anesthetics - - - 459 83 -4 N01BX04 capsaicin - - - 459 83 -4 N02 ANALGESICS 61,69 5 5 82 319 11 10 N02A OPIOIDS 13,54 6 -3 24 829 24 -4 N02AA Natural opium alkaloids 1,96 23 0 10 347 49 1 N02AA01 morphine 0,10 86 5 1 650 87 18 N02AA03 hydromorphone 0,05 33 -12 544 70 -12 N02AA05 oxycodone 1,54 17 1 4 956 45 -3 N02AA55 oxycodone and naloxone 0,28 32 -5 3 196 30 4 N02AB Phenylpiperidine derivatives 1,28 15 -12 3 073 17 -5 Page 51 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

N02AB03 fentanyl 1,28 15 -12 3 073 17 -5 N02AE Oripavine derivatives 1,49 5 1 5 104 7 -1 N02AE01 buprenorphine 1,49 5 1 5 104 7 -1 N02AJ Opioids in combination with non-opioid analgesics 6,26 1 -4 3 230 1 -12 N02AJ06 codeine and paracetamol 5,69 1 -4 2 749 1 -11 N02AJ08 codeine and ibuprofen 0,11 0 -8 265 0 -10 N02AJ13 tramadol and paracetamol 0,46 1 8 208 1 -28 N02AJ14 taramadol and dexketoprofen - - - 9 0 15 N02AX Other opioids 2,54 2 -3 3 075 4 -15 N02AX02 tramadol 2,54 2 -3 3 075 4 -15 N02B OTHER ANALGESICS AND ANTIPYRETICS 43,19 4 7 31 590 9 11 N02BA Salicylic acid and derivatives 1,82 0 57 3 388 0 125 N02BA01 acetylsalicylic acid 0,73 1 -5 1 033 1 4 N02BA51 acetylsalicylic acid, combinations excl. 1,09 0 182 2 355 0 363 psycholeptics N02BE Anilides 41,37 5 6 28 012 10 5 N02BE01 paracetamol 41,17 5 6 27 412 10 6 N02BE51 paracetamol, combinations excl. psycholeptics 0,20 0 -28 600 0 -31 N02BG Other analgesics and antipyretics 0,00 17 -4 189 52 5 N02BG09 methoxyflurane - - - 88 94 17 N02BG10 cannabinoids 0,00 17 -4 101 17 -4 N02C ANTIMIGRAINE PREPARATIONS 4,96 0 8 25 900 0 27 N02CC Selective 5HT1-receptor agonists 4,17 1 -1 7 876 1 -2 N02CC01 sumatriptan 3,29 1 -1 4 718 1 -2 N02CC02 naratriptan 0,03 0 1 79 0 -15 N02CC03 zolmitriptan 0,19 1 -3 865 1 -5 N02CC04 rizatriptan 0,14 1 5 700 1 5 N02CC05 almotriptan 0,11 0 4 440 0 -2 N02CC06 eletriptan 0,24 0 5 479 0 -12 N02CC07 frovatriptan 0,17 0 5 595 0 4 N02CD Calcitonin gene-related peptide (CGRP) 0,80 0 94 18 024 0 47 antagonists N02CD01 erenumab 0,63 0 54 13 284 0 8 N02CD02 galcanezumab 0,01 1 - 288 1 - Page 52 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

N02CD03 fremanezumab 0,16 0 17 568 4 452 0 15 523 N03 ANTIEPILEPTICS 24,30 4 5 47 959 9 -9 N03A ANTIEPILEPTICS 24,30 4 5 47 959 9 -9 N03AB Hydantoin derivatives 0,15 8 -17 723 86 -31 N03AB02 phenytoin 0,14 5 -16 107 5 -16 N03AB05 fosphenytoin 0,01 100 -33 616 100 -33 N03AE Benzodiazepine derivatives 0,64 2 -7 471 2 -6 N03AE01 clonazepam 0,64 2 -7 471 2 -6 N03AF Carboxamide derivatives 3,58 2 -1 4 993 3 1 N03AF01 carbamazepine 1,26 2 -5 1 097 6 -5 N03AF02 oxcarbazepine 2,25 2 2 3 180 2 2 N03AF03 rufinamide 0,02 5 7 235 5 7 N03AF04 eslicarbazepine 0,06 2 8 481 2 8 N03AG Fatty acid derivatives 3,57 6 -1 4 700 9 0 N03AG01 valproic acid 3,55 6 -1 4 617 9 0 N03AG04 vigabatrin 0,02 9 0 83 9 0 N03AX Other antiepileptics 16,36 4 8 37 073 8 -11 N03AX09 lamotrigine 2,32 2 4 4 559 3 -4 N03AX11 topiramate 0,36 5 -1 1 504 4 -4 N03AX12 gabapentin 4,24 5 19 6 542 5 6 N03AX14 levetiracetam 2,78 6 3 8 698 8 1 N03AX15 zonisamide 0,19 2 1 833 2 -3 N03AX16 pregabalin 5,57 3 3 6 564 3 -48 N03AX17 stiripentol 0,01 3 7 341 3 7 N03AX18 lacosamide 0,61 7 16 5 561 21 15 N03AX22 perampanel 0,09 5 10 958 6 8 N03AX23 brivaracetam 0,20 5 75 1 513 14 58 N04 ANTI-PARKINSON DRUGS 5,07 4 -4 16 893 4 -2 N04A ANTICHOLINERGIC AGENTS 0,16 5 -4 91 5 -4 N04AA Tertiary amines 0,16 5 -4 91 5 -4 N04AA02 biperiden 0,16 5 -4 91 5 -4 N04B DOPAMINERGIC AGENTS 4,90 4 -4 16 803 4 -2 N04BA Dopa and dopa derivatives 2,31 5 -6 13 127 4 0 N04BA02 levodopa and decarboxylase inhibitor 1,60 5 -8 10 853 4 -3 Page 53 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

N04BA03 levodopa, decarboxylase inhibitor and COMT 0,71 5 -1 2 274 6 19 inhibitor N04BC Dopamine agonists 1,46 2 1 3 006 3 -11 N04BC01 bromocriptine 0,00 18 7 6 18 7 N04BC04 ropinirole 0,68 2 -3 464 2 -21 N04BC05 pramipexole 0,67 3 5 1 514 3 -16 N04BC06 cabergoline 0,01 6 4 74 6 4 N04BC07 apomorphine 0,02 2 10 380 2 10 N04BC09 rotigotine 0,09 3 1 568 3 0 N04BD Monoamine oxidase type B inhibitors 1,10 4 -5 500 4 -10 N04BD01 selegiline 0,73 3 -6 342 3 -7 N04BD02 rasagiline 0,37 7 -1 158 6 -17 N04BD03 safinamide 0,00 19 100 1 20 100 N04BX Other dopamingergic agents 0,03 6 9 169 6 9 N04BX02 entacapone 0,03 6 9 169 6 9 N05 PSYCHOLEPTICS 86,68 5 3 73 129 14 4 N05A ANTIPSYCHOTICS 22,15 7 4 51 762 11 3 N05AA Phenothiazines with aliphatic side chain 0,31 6 -6 347 6 -4 N05AA02 levomepromazine 0,31 6 -6 347 6 -4 N05AB Phenothiazines with piperazine structure 0,36 4 -2 568 5 -1 N05AB03 perphenazine 0,34 4 -2 549 6 0 N05AB04 prochlorperazine 0,01 2 -7 19 2 -7 N05AD Butyrophenone derivatives 0,35 30 3 499 50 -1 N05AD01 haloperidol 0,33 27 4 360 32 4 N05AD08 droperidol 0,02 97 -11 139 97 -11 N05AE Indole derivatives 0,33 6 4 1 551 7 5 N05AE03 sertindole 0,06 4 -6 387 4 -6 N05AE04 ziprasidone 0,16 3 -2 592 4 -2 N05AE05 lurasidone 0,10 11 25 572 12 23 N05AF Thioxanthene derivatives 0,53 8 -2 579 13 -3 N05AF01 flupentixol 0,05 3 0 69 3 -1 N05AF03 chlorprothixene 0,24 3 -6 247 3 -5 N05AF05 zuclopenthixol 0,24 15 1 263 24 0 N05AH Diazepines, oxazepines, thiazepines and oxepines 14,52 7 5 20 079 12 1 Page 54 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

N05AH02 clozapine 2,36 9 5 3 884 9 0 N05AH03 olanzapine 6,66 8 6 12 282 16 2 N05AH04 quetiapine 5,48 4 3 3 798 3 -1 N05AH05 asenapine 0,02 12 -3 114 15 -6 N05AL Benzamides 0,04 9 2 102 8 1 N05AL01 sulpiride 0,04 9 2 102 8 1 N05AN Lithium 0,99 6 1 621 6 1 N05AN01 lithium 0,99 6 1 621 6 1 N05AX Other antipsychotics 4,73 7 5 27 415 10 4 N05AX08 risperidone 1,72 6 2 8 669 5 -7 N05AX12 aripiprazole 2,70 6 5 8 269 10 9 N05AX13 paliperidone 0,27 12 11 10 257 12 9 N05AX15 cariprazine 0,03 53 146 143 56 135 N05AX16 brexpiprazole 0,01 24 669 77 23 704 N05B ANXIOLYTICS 15,48 6 -4 6 937 26 15 N05BA Benzodiazepine derivatives 14,04 6 -5 5 607 30 19 N05BA01 diazepam 3,98 9 -7 1 314 28 -10 N05BA04 oxazepam 4,70 4 -3 1 698 4 -3 N05BA06 lorazepam 1,79 13 -1 1 578 78 254 N05BA09 clobazam 0,38 4 14 129 4 14 N05BA12 alprazolam 3,19 1 -8 888 1 -7 N05BB Diphenylmethane derivatives 1,20 5 -1 726 4 0 N05BB01 hydroxyzine 1,20 5 -1 726 4 0 N05BE Azaspirodecanedione derivatives 0,25 12 2 604 12 3 N05BE01 buspirone 0,25 12 2 604 12 3 N05C HYPNOTICS AND SEDATIVES 49,04 4 5 14 431 21 3 N05CD Benzodiazepine derivatives 5,31 6 -9 3 515 16 4 N05CD02 nitrazepam 0,26 2 -14 102 2 -8 N05CD05 triazolam 0,03 0 -17 33 0 -17 N05CD07 temazepam 4,78 4 -10 1 800 3 0 N05CD08 midazolam 0,24 58 8 1 579 32 11 N05CF Benzodiazepine related drugs 16,02 2 -4 2 506 2 0 N05CF01 zopiclone 11,43 3 -5 1 886 2 -1 N05CF02 zolpidem 4,59 1 0 620 1 4 Page 55 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

N05CH Melatonin receptor agonists 27,49 4 15 5 810 4 13 N05CH01 melatonin 27,49 4 15 5 810 4 13 N05CM Other hypnotics and sedatives 0,22 6 109 2 600 83 -12 N05CM09 Valerianae radix 0,21 0 123 451 0 207 N05CM18 dexmedetomidine 0,01 100 6 2 149 100 -24 N06 PSYCHOANALEPTICS 106,12 2 5 58 446 3 8 N06A ANTIDEPRESSANTS 81,53 2 4 36 018 2 8 N06AA Non-selective monoamine reuptake inhibitors 3,92 2 -5 3 420 2 4 N06AA04 clomipramine 0,22 4 9 161 4 9 N06AA06 trimipramine 0,09 2 6 65 2 6 N06AA09 amitriptyline 3,01 2 4 2 759 2 11 N06AA10 nortriptyline 0,60 2 4 436 2 3 N06AA12 doxepin - - -100 0 - -100 N06AB Selective serotonin reuptake inhibitors 44,59 2 3 6 824 2 3 N06AB03 fluoxetine 4,51 2 3 1 093 2 5 N06AB04 citalopram 8,50 1 -6 1 343 2 -8 N06AB05 paroxetine 2,33 1 1 652 1 -7 N06AB06 sertraline 10,87 2 12 1 611 2 14 N06AB08 fluvoxamine 0,14 1 -2 76 1 -2 N06AB10 escitalopram 18,23 1 3 2 048 2 6 N06AG Monoamine oxidase type A inhibitors 0,34 1 0 268 1 0 N06AG02 moclobemide 0,34 1 0 268 1 0 N06AX Other antidepressants 32,69 2 8 25 506 3 9 N06AX03 mianserin 0,20 2 -22 190 2 -21 N06AX05 trazodone 0,20 3 6 179 3 6 N06AX11 mirtazapine 8,47 4 3 5 080 4 10 N06AX12 bupropion 2,53 1 9 4 057 1 -1 N06AX16 venlafaxine 11,67 2 6 6 982 2 8 N06AX17 milnacipran 0,02 1 -48 23 1 -55 N06AX18 reboxetin 0,03 2 -9 30 2 -9 N06AX21 duloxetine 4,14 2 6 1 308 4 7 N06AX22 agomelatine 1,04 2 14 778 2 -10 N06AX26 vortioxetine 4,39 2 27 6 834 2 23 N06AX27 esketamine - - - 45 73 - Page 56 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

N06B PSYCHOSTIMULANTS, AGENTS USED FOR 6,70 1 21 16 115 3 17 ADHD AND NOOTROPICS N06BA Centrally acting sympathomimetics 6,65 1 21 15 562 1 17 N06BA02 dexamfetamine 0,15 0 16 739 0 14 N06BA04 methylphenidate 4,95 1 16 8 107 1 13 N06BA07 modafinil 0,08 1 -1 766 1 -1 N06BA09 atomoxetine 0,20 4 17 876 5 -32 N06BA12 lisdexamfetamine 1,27 1 52 5 075 1 48 N06BC Xanthine derivatives 0,00 100 -8 253 100 -8 N06BC01 caffeine 0,00 100 -8 253 100 -8 N06BX Other psychostimulants and nootropics 0,05 3 -1 300 1 137 N06BX03 piracetam 0,05 3 -2 52 3 -3 N06BX13 idebenone 0,00 0 247 248 0 240 N06C PSYCHOLEPTICS AND PSYCHOANALEPTICS 1,09 1 13 439 1 -4 IN COMBINATION N06CA Antidepressants in combination with psycholeptics 1,09 1 13 439 1 -4 N06CA01 amitriptyline and psycholeptics 1,09 1 13 439 1 -4 N06D ANTI-DEMENTIA DRUGS 16,79 4 1 5 875 5 -6 N06DA Anticholinesterases 9,92 4 0 4 452 5 2 N06DA02 donepezil 5,93 3 -1 649 3 39 N06DA03 rivastigmine 2,33 5 1 2 471 6 -6 N06DA04 galantamine 1,66 4 5 1 332 4 6 N06DX Other anti-dementia drugs 6,87 5 2 1 423 6 -24 N06DX01 memantine 6,87 5 2 1 423 6 -24 N07 OTHER NERVOUS SYSTEM DRUGS 42,75 81 17 88 735 83 22 N07A PARASYMPATHOMIMETICS 0,27 5 -1 489 43 6 N07AA Anticholinesterases 0,27 5 -1 477 44 7 N07AA02 pyridostigmine 0,26 2 -1 271 2 -2 N07AA51 neostigmine, combinations 0,01 99 22 206 99 22 N07AX Other parasympathomimetics 0,00 1 -21 12 1 -21 N07AX01 pilocarpine 0,00 1 -21 12 1 -21 N07B DRUGS USED IN ADDICTIVE DISORDERS 39,61 88 19 85 287 86 22 N07BA Drugs used in nicotine dependence 38,14 89 20 75 109 86 16 N07BA01 nicotine 37,49 91 20 71 691 90 17 Page 57 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

N07BA03 varenicline 0,65 1 2 3 418 1 2 N07BB Drugs used in alcohol dependence 0,63 7 -3 604 6 -6 N07BB01 disulfiram 0,53 7 -3 396 7 -3 N07BB04 naltrexone 0,09 5 0 156 5 -1 N07BB05 nalmefene 0,01 2 -31 52 2 -31 N07BC Drugs used in opioid dependence 0,85 85 10 9 575 93 119 N07BC01 buprenorphine 0,14 97 331 7 415 97 326 N07BC02 methadone 0,61 86 -2 1 586 90 -2 N07BC05 levomethadone 0,02 73 - 74 73 - N07BC51 buprenorphine, combinations 0,08 56 -32 500 52 -51 N07C ANTIVERTIGO PREPARATIONS 2,80 1 2 706 1 1 N07CA Antivertigo preparations 2,80 1 2 706 1 1 N07CA01 betahistine 2,80 1 2 705 1 1 N07CA52 cinnarizine, combinations 0,00 0 -11 1 0 -11 N07X OTHER NERVOUS SYSTEM DRUGS 0,06 4 13 2 253 8 10 N07XX Other nervous system drugs 0,06 4 13 2 253 8 10 N07XX02 riluzole 0,02 8 9 210 8 17 N07XX04 sodium oxybate 0,03 1 9 1 100 1 -19 N07XX06 tetrabenazine 0,00 11 -21 63 11 -21 N07XX07 fampridine 0,01 5 32 106 7 45 N07XX08 tafamidis 0,00 22 131 654 22 129 N07XX11 pitolisant 0,00 0 168 120 0 77 P ANTIPARASITIC PRODUCTS, INSECTICIDES 2,53 3 4 5 780 4 -8 AND REPELLENTS P01 ANTIPROTOZOALS 2,26 4 6 2 699 6 -12 P01A AGENTS AGAINST AMOEBIASIS AND OTHER 0,28 14 -8 690 11 -10 PROTOZOAL DISEASES P01AB Nitroimidazole derivatives 0,28 14 -8 690 11 -10 P01AB01 metronidazole 0,28 14 -8 690 11 -10 P01B ANTIMALARIALS 1,98 2 9 2 009 4 -13 P01BA Aminoquinolines 1,97 2 10 1 754 2 10 P01BA02 hydroxychloroquine 1,97 2 10 1 754 2 10 P01BB Biguanides 0,01 19 -63 217 20 -65 P01BB51 proguanil, combinations 0,01 19 -63 217 20 -65 Page 58 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

P01BC Quinine alkaloids 0,00 6 -64 37 6 -64 P01BC02 mefloquine 0,00 6 -64 37 6 -64 P02 ANTHELMINTICS 0,27 0 -8 1 515 0 -10 P02C ANTINEMATODAL AGENTS 0,27 0 -8 1 515 0 -10 P02CX Other antinematodals 0,27 0 -8 1 515 0 -10 P02CX01 pyrvinium 0,27 0 -8 1 515 0 -10 P03 ECTOPARASITICIDES, INCL. SCABICIDES, - - - 1 566 4 1 INSECTICIDES AND REPELLENTS P03A ECTOPARASITICIDES, INCL. SCABICIDES - - - 1 566 4 1 P03AC Pyrethrines, incl. synthetic compounds - - - 1 566 4 1 P03AC04 permethrin - - - 1 566 4 1 R RESPIRATORY SYSTEM 183,53 2 2 148 654 6 -3 R01 NASAL PREPARATIONS 33,74 1 -10 23 805 1 -12 R01A DECONGESTANTS AND OTHER NASAL 31,97 1 -9 19 756 1 -6 PREPARATIONS FOR TOPICAL USE R01AA Sympathomimetics, plain 9,17 1 -17 5 294 1 -10 R01AA05 oxymetazoline 0,75 0 -8 260 0 -8 R01AA07 xylometazoline 8,42 1 -18 5 034 1 -10 R01AB Sympathomimetics, combinations excl. 0,64 0 -22 492 0 -20 corticosteroids R01AB06 xylometazoline 0,64 0 -22 492 0 -20 R01AC Antiallergic agents, excl. corticosteroids 0,22 0 -35 246 0 -19 R01AC01 cromoglicic acid 0,03 0 -85 21 0 -84 R01AC02 levocabastine 0,09 0 39 137 0 39 R01AC03 azelastine 0,09 0 23 87 0 23 R01AD Corticosteroids 21,63 1 -4 13 275 1 -3 R01AD01 beclometasone 1,04 1 -2 535 0 6 R01AD05 budesonide 0,23 0 -50 92 0 -50 R01AD08 fluticasone 4,43 1 -1 2 361 1 0 R01AD09 mometasone 5,86 1 -7 1 866 1 -19 R01AD11 triamcinolone 0,67 0 6 537 0 6 R01AD12 fluticasone furoate 4,65 1 -6 2 836 1 -6 R01AD58 fluticasone, combinations 4,75 0 5 5 048 0 4 R01AX Other nasal preparations 0,31 4 -10 449 16 2 Page 59 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

R01AX03 ipratropium bromide 0,13 6 12 186 7 13 R01AX06 mupirocin - - - 163 35 9 R01AX10 various 0,18 3 -21 100 3 -21 R01B NASAL DECONGESTANTS FOR SYSTEMIC USE 1,77 2 -33 4 049 1 -33 R01BA Sympathomimetics 1,77 2 -33 4 049 1 -33 R01BA01 phenylpropanolamine 0,13 5 -7 50 5 -9 R01BA52 pseudoephedrine, combinations 1,63 1 -35 3 999 1 -33 R02 THROAT PREPARATIONS 2,51 0 -23 5 708 0 -24 R02A THROAT PREPARATIONS 2,51 0 -23 5 708 0 -24 R02AA Antiseptics 1,06 0 -30 2 977 0 -30 R02AA03 dichlorobenzyl alcohol 1,05 0 -30 2 626 0 -28 R02AA05 chlorhexidine 0,01 5 -56 12 5 -56 R02AA20 various - - - 338 2 -43 R02AB Antibiotics 1,06 1 -9 2 065 1 -7 R02AB30 gramicidin 1,06 1 -9 2 065 1 -7 R02AX Other throat preparations 0,38 0 -34 667 0 -37 R02AX01 flurbiprofen 0,04 0 -40 169 0 -38 R02AX03 benzydamine 0,35 0 -33 498 0 -37 R03 DRUGS FOR OBSTRUCTIVE AIRWAY 71,99 4 4 93 811 8 3 DISEASES R03A ADRENERGICS, INHALANTS 37,68 3 8 55 921 3 4 R03AC Selective beta-2-adrenoceptor agonists 2,34 3 -1 7 567 3 -2 R03AC02 salbutamol 1,05 6 -1 5 334 3 -3 R03AC03 terbutaline 0,12 1 2 519 1 2 R03AC12 salmeterol 0,34 1 0 481 1 0 R03AC13 formoterol 0,66 1 2 966 1 2 R03AC18 indacaterol 0,12 3 -13 160 3 -12 R03AC19 olodaterol 0,07 3 -12 107 3 -12 R03AK Adrenergics in combination with corticosteroids or 31,98 2 8 38 253 2 1 other drugs, excl. anticholinergics R03AK06 salmeterol and fluticasone 9,86 4 1 9 864 4 -20 R03AK07 formoterol and budesonide 14,41 1 5 15 132 1 5 R03AK08 formoterol and beclometasone 3,81 2 24 4 497 2 22 R03AK10 vilanterol and fluticasone furoate 2,90 1 23 6 389 1 21 Page 60 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

R03AK11 formoterol and fluticasone 0,99 2 11 2 369 2 10 R03AK14 indacaterol and mometasone - - - 1 0 - R03AL Adrenergics in combination with anticholinergics 3,36 10 19 10 101 6 25 incl. triple combinations with corticosteroids R03AL01 fenoterol and ipratropium bromide 0,55 24 23 307 27 11 R03AL02 salbutamol and ipratropium bromide 0,24 41 -21 281 41 -32 R03AL03 vilanterol and umeclidinium bromide 0,40 2 7 1 170 2 4 R03AL04 indacaterol and glycopyrronium bromide 0,13 2 -16 369 2 -18 R03AL05 formoterol and aclidinium bromide 0,05 2 -14 142 2 -16 R03AL06 olodaterol and tiotropium bromide 0,82 5 10 2 342 5 8 R03AL07 formoterol and glycopyrronium bromide 0,01 3 213 21 3 213 R03AL08 vilanterol, umeclidinium bromide and fluticasone 0,67 3 53 2 585 3 53 furoate R03AL09 formoterol, glycopyrronium bromide and 0,51 10 64 2 884 7 59 beclometasone R03AL12 indacaterol, glycopyrroinium bromide and 0,00 0 - 1 0 - mometasone R03B OTHER DRUGS FOR OBSTRUCTIVE AIRWAY 25,16 4 -2 28 243 3 0 DISEASES, INHALANTS R03BA Glucocorticoids 20,30 2 5 17 162 3 1 R03BA01 beclometasone 2,53 2 2 2 426 2 2 R03BA02 budesonide 4,70 4 2 4 728 4 4 R03BA05 fluticasone 5,60 3 4 6 208 3 -5 R03BA07 mometasone 0,16 1 -7 150 1 -6 R03BA08 ciclesonide 7,31 1 10 3 650 1 10 R03BB Anticholinergics 4,87 13 -23 11 081 5 -3 R03BB01 ipratropium bromide 1,05 48 -18 281 45 7 R03BB04 tiotropium bromide 3,46 3 -26 10 072 4 -2 R03BB05 aclidinium bromide 0,04 2 -10 74 2 -13 R03BB06 glycopyrronium bromide 0,08 1 -13 154 1 -17 R03BB07 umeclidinium bromide 0,24 2 4 501 2 -1 R03C ADRENERGICS FOR SYSTEMIC USE 0,03 4 -25 74 3 -29 R03CC Selective beta-2-adrenoceptor agonists 0,03 4 -25 74 3 -29 R03CC02 salbutamol 0,03 4 -25 74 3 -29 Page 61 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

R03D OTHER SYSTEMIC DRUGS FOR 9,13 2 4 9 573 48 8 OBSTRUCTIVE AIRWAY DISEASES R03DA Xanthines 0,65 3 -8 196 3 -25 R03DA04 theophylline 0,64 3 -5 193 3 -1 R03DA05 aminophylline 0,00 4 -81 1 4 -81 R03DA54 theophylline, combinations excl. psycholeptics 0,00 4 -97 2 4 -97 R03DC Leukotriene receptor antagonists 8,29 1 5 1 301 1 -2 R03DC01 zafirlukast - - -100 0 - -100 R03DC03 montelukast 8,29 1 5 1 301 1 -2 R03DX Other systemic drugs for obstructive airway 0,19 32 10 8 077 56 11 diseases R03DX05 omalizumab 0,05 40 7 3 347 40 1 R03DX07 roflumilast 0,09 4 -3 217 5 -2 R03DX08 reslizumab 0,00 100 -51 179 100 -51 R03DX09 mepolizumab 0,03 63 26 2 756 68 6 R03DX10 benralizumab 0,02 71 143 1 577 74 105 R05 COUGH AND COLD PREPARATIONS 3,61 2 -36 7 100 2 -33 R05C EXPECTORANTS, EXCL. COMBINATIONS 1,94 4 -28 3 077 5 -28 WITH COUGH SUPPRESSANTS R05CA Expectorants 0,09 0 -34 112 0 -29 R05CA03 guaifenesin - - -100 0 - -100 R05CA10 combinations 0,09 0 -28 112 0 -22 R05CB Mucolytics 1,85 4 -28 2 965 5 -28 R05CB01 acetylcysteine 0,53 4 -26 562 3 -27 R05CB02 bromhexine 0,72 0 -28 968 0 -29 R05CB03 carbocisteine 0,03 1 -39 58 1 -39 R05CB06 ambroxol 0,18 4 -35 429 4 -37 R05CB13 dornase alfa (desoxyribonuclease) 0,01 11 8 388 11 8 R05CB15 erdosteine 0,37 11 -26 561 11 -32 R05D COUGH SUPPRESSANTS, EXCL. 0,69 1 -35 1 561 1 -33 COMBINATIONS WITH EXPECTORANTS R05DA Opium alkaloids and derivatives 0,57 1 -37 1 202 1 -35 R05DA01 ethylmorphine 0,16 1 -41 579 1 -33 R05DA09 dextromethorphan 0,42 1 -35 622 1 -36 Page 62 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

R05DB Other cough suppressants 0,12 0 -25 359 0 -27 R05DB05 pentoxyverine 0,12 0 -25 359 0 -27 R05F COUGH SUPPRESSANTS AND 0,97 0 -47 1 968 0 -44 EXPECTORANTS, COMBINATIONS R05FA Opium derivatives and expectorants 0,64 0 -54 589 0 -66 R05FA02 opium derivatives and expectorants 0,64 0 -54 589 0 -66 R05FB Other cough suppressants and expectorants 0,33 0 -24 1 380 0 -22 R05FB02 cough suppressants and expectorants 0,33 0 -24 1 380 0 -22 R05X OTHER COLD PREPARATIONS - - - 494 0 -18 R06 ANTIHISTAMINES FOR SYSTEMIC USE 71,69 1 12 17 203 1 8 R06A ANTIHISTAMINES FOR SYSTEMIC USE 71,69 1 12 17 203 1 8 R06AA Aminoalkyl ethers 0,10 1 28 137 2 26 R06AA09 doxylamine 0,10 1 28 137 2 26 R06AE Piperazine derivatives 38,29 2 9 9 372 1 10 R06AE03 cyclizine 0,00 0 - 14 0 - R06AE05 meclozine 0,09 0 -53 234 0 -47 R06AE07 cetirizine 33,18 2 10 7 619 1 15 R06AE09 levocetirizine 5,01 0 6 1 505 0 3 R06AX Other antihistamines for systemic use 33,30 0 15 7 694 0 6 R06AX13 loratadine 3,53 0 15 751 0 18 R06AX18 acrivastine 0,08 0 0 144 0 0 R06AX22 ebastine 9,16 0 20 2 541 0 9 R06AX26 fexofenadine 4,20 0 9 1 733 0 4 R06AX27 desloratadine 15,92 1 14 2 338 1 1 R06AX29 bilastine 0,41 0 7 187 0 7 R07 OTHER RESPIRATORY SYSTEM PRODUCTS 0,00 87 42 1 027 83 48 R07A OTHER RESPIRATORY SYSTEM PRODUCTS 0,00 87 42 1 027 83 48 R07AA Lung surfactants 0,00 100 24 857 100 24 R07AA02 natural phopholipids 0,00 100 24 857 100 24 R07AX Other respiratory system products 0,00 0 - 170 0 - R07AX02 ivacaftor 0,00 0 - 85 0 - R07AX31 ivacaftor and tezacaftor - - - 85 0 - S SENSORY ORGANS 24,74 2 3 68 873 45 1 S01 OPHTHALMOLOGICALS 24,74 2 3 66 896 46 2 Page 63 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

S01A ANTIINFECTIVES - - - 3 792 17 -19 S01AA Antibiotics - - - 3 103 19 -22 S01AA01 chloramphenicol - - - 2 680 17 -21 S01AA12 tobramycin - - - 15 23 -3 S01AA13 fusidic acid - - - 276 8 -34 S01AA26 azithromycin - - - 30 1 -50 S01AA27 cefuroxime - - - 103 87 14 S01AD Antivirals - - - 34 11 715 S01AD03 aciclovir - - - 34 11 715 S01AE Fluoroquinolones - - - 655 12 -4 S01AE01 ofloxacin - - - 79 35 -34 S01AE05 levofloxacin - - - 563 8 2 S01AE07 moxifloxacin - - - 13 36 -3 S01B ANTIINFLAMMATORY AGENTS - - - 3 845 39 5 S01BA Corticosteroids, plain - - - 3 043 49 5 S01BA01 dexamethasone - - - 1 590 73 6 S01BA02 hydrocortisone - - - 113 1 24 S01BA04 prednisolone - - - 856 4 -2 S01BA05 triamcinolone - - - 283 100 26 S01BA07 fluorometholone - - - 201 1 -7 S01BC Antiinflammatory agents, non-steroids - - - 802 2 5 S01BC03 diclofenac - - - 93 12 8 S01BC10 nepafenac - - - 645 1 4 S01BC11 bromfenac - - - 64 0 16 S01C ANTIINFLAMMATORY AGENTS AND - - - 1 100 20 -3 ANTIINFECTIVES IN COMBINATION S01CA Corticosteroids and antiinfectives in combination - - - 1 100 20 -3 S01CA01 dexamethasone and antiinfectives - - - 825 23 -4 S01CA03 hydrocortisone and antiinfectives - - - 274 9 -3 S01E ANTIGLAUCOMA PREPARATIONS AND 24,74 2 3 14 595 3 0 MIOTICS S01EA Sympathomimetics in glaucoma therapy 0,58 8 -7 422 30 -7 S01EA03 apraclonidine 0,04 60 -4 148 77 -5 S01EA05 brimonidine 0,54 4 -7 274 4 -7 Page 64 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

S01EB Parasympathomimetics 0,10 13 -10 41 57 10 S01EB01 pilocarpine 0,10 13 -10 17 13 -10 S01EB09 acetylcholine - - - 25 86 29 S01EC Carbonic anhydrase inhibitors 2,88 3 3 1 389 3 2 S01EC03 dorzolamide 0,18 3 -2 121 3 -4 S01EC04 brinzolamide 2,12 3 3 761 3 3 S01EC54 brinzolamide, combinations 0,58 2 3 506 2 3 S01ED Beta blocking agents 9,39 2 4 6 933 2 -3 S01ED01 timolol 0,51 3 -12 286 2 2 S01ED02 betaxolol 0,30 3 -2 78 3 -3 S01ED51 timolol, combinations 8,59 2 5 6 569 2 -3 S01EE Prostaglandin analogues 11,79 2 4 5 810 2 4 S01EE01 latanoprost 5,10 2 2 1 988 2 9 S01EE03 bimatoprost 3,87 1 9 909 2 -1 S01EE04 travoprost 0,79 3 -10 686 2 -13 S01EE05 tafluprost 2,03 1 5 2 227 1 7 S01F MYDRIATICS AND CYCLOPLEGICS - - - 655 59 4 S01FA Anticholinergics - - - 572 58 3 S01FA01 atropine - - - 37 34 26 S01FA02 scopolamine - - - 0 - -100 S01FA04 cyclopentolate - - - 113 41 15 S01FA06 tropicamide - - - 283 53 12 S01FA56 tropicamide, combinations - - - 139 87 4 S01FB Sympathomimetics excl. antiglaucoma - - - 83 71 8 preparations S01FB01 phenylephrine - - - 83 71 8 S01G DECONGESTANTS AND ANTIALLERGICS - - - 3 310 1 -13 S01GA Sympathomimetics used as decongestants - - - 201 0 -20 S01GA02 tetryzoline - - - 201 0 -20 S01GX Other antiallergics - - - 3 109 1 -13 S01GX01 cromoglicic acid - - - 2 304 1 -12 S01GX02 levocabastine - - - 176 0 44 S01GX05 lodoxamide - - - 35 0 -37 S01GX06 emedastine - - - 27 0 -22 Page 65 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

S01GX07 azelastine - - - 0 - -100 S01GX08 ketotifen - - - 516 1 -19 S01GX09 olopatadine - - - 52 0 -17 S01H LOCAL ANESTHETICS - - - 245 79 4 S01HA Local anesthetics - - - 245 79 4 S01HA02 oxybuprocaine - - - 245 79 4 S01J DIAGNOSTIC AGENTS - - - 206 59 8 S01JA Colouring agents - - - 206 59 8 S01JA01 fluorescein - - - 17 97 17 S01JA51 fluorescein, combinations - - - 189 56 7 S01L OCULAR VASCULAR DISORDER AGENTS - - - 26 785 100 9 S01LA Antineovascularisation agents - - - 26 785 100 9 S01LA01 verteporfin - - - 161 100 -4 S01LA04 ranibizumab - - - 299 100 -9 S01LA05 aflibercept - - - 26 271 100 9 S01LA06 brolucizumab - - - 54 100 - S01X OTHER OPHTHALMOLOGICALS - - - 12 364 3 1 S01XA Other ophthalmologicals - - - 12 364 3 1 S01XA02 retinol - - - 529 3 2 S01XA18 ciclosporin - - - 660 1 10 S01XA20 artificial tears and other indifferent preparations - - - 11 125 3 0 S01XA21 mercaptamine - - - 51 0 - S02 OTOLOGICALS - - - 1 785 3 -6 S02A ANTIINFECTIVES - - - 736 2 3 S02AA Antiinfectives - - - 736 2 3 S02AA03 boric acid - - - 719 2 4 S02AA15 ciprofloxacin - - - 17 2 -31 S02B CORTICOSTEROIDS - - - 16 0 51 S02BA Corticosteroids - - - 16 0 51 S02BA08 fluocinolone acetonide - - - 16 0 51 S02C CORTICOSTEROIDS AND ANTIINFECTIVES IN - - - 919 3 -4 COMBINATION S02CA Corticosteroids and antiinfectives in combination - - - 919 3 -4 S02CA02 flumetasone and antiinfectives - - - 224 4 24 Page 66 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

S02CA03 hydrocortisone and antiinfectives - - - 378 4 -22 S02CA05 fluocinolone acetonide and antiinfectives - - - 317 2 9 S02D OTHER OTOLOGICALS - - - 115 1 -44 S02DA Analgesics and anesthetics - - - 115 1 -44 S02DA04 cinchocaine - - - 115 1 -44 S03 OPHTHALMOLOGICAL AND OTOLOGICAL - - - 191 16 -8 PREPARATIONS S03C CORTICOSTEROIDS AND ANTIINFECTIVES IN - - - 191 16 -8 COMBINATION S03CA Corticosteroids and antiinfectives in combination - - - 191 16 -8 S03CA04 hydrocortisone and antiinfectives - - - 191 16 -8 V VARIOUS 0,19 42 4 39 784 86 2 V01 ALLERGENS - - - 4 979 46 53 V01A ALLERGENS - - - 4 979 46 53 V01AA Allergen extracts - - - 4 979 46 53 V01AA02 grass pollen - - - 846 0 20 V01AA03 house dust mites - - - 50 22 16 V01AA05 tree pollen - - - 3 736 53 69 V01AA07 insects - - - 215 99 10 V01AA11 animals - - - 131 78 29 V01AA20 various - - - 1 84 24 V03 ALL OTHER THERAPEUTIC PRODUCTS 0,19 42 4 9 360 74 -4 V03A ALL OTHER THERAPEUTIC PRODUCTS 0,19 42 4 9 360 74 -4 V03AB Antidotes - - - 5 451 94 2 V03AB14 protamine - - - 251 100 -19 V03AB15 naloxone - - - 261 92 42 V03AB17 methylthioninium chloride - - - 108 99 -18 V03AB21 potassium iodide - - - 455 44 77 V03AB25 flumazenil - - - 80 99 15 V03AB33 hydroxocobalamin - - - 159 97 5 V03AB34 fomepizole - - - 85 100 -40 V03AB35 sugammadex - - - 3 431 99 2 V03AB37 idarucizumab - - - 198 100 -29 V03AB38 andexanet alfa - - - 422 100 -8 Page 67 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

V03AC Iron chelating agents - - - 1 011 6 -3 V03AC01 deferoxamine - - - 19 85 -2 V03AC02 deferiprone - - - 0 - -100 V03AC03 deferasirox - - - 992 5 -2 V03AE Drugs for treatment of hyperkalemia and 0,13 18 2 1 261 17 4 hyperphosphatemia V03AE01 polystyrene sulphonate 0,03 23 -8 105 23 -8 V03AE02 sevelamer 0,04 16 3 401 16 5 V03AE03 lanthanum carbonate 0,06 15 1 715 16 1 V03AE05 sucroferric oxyhydroxide 0,00 12 169 14 12 169 V03AE09 patiromer calcium 0,00 45 558 26 45 505 V03AF Detoxifying agents for cytostatic treatment 0,06 95 10 1 636 94 -24 V03AF01 mesna - - - 448 100 -16 V03AF02 dexrazoxane 0,00 100 -64 133 100 -64 V03AF03 calcium folinate 0,06 95 11 625 84 -20 V03AF07 rasburicase 0,00 100 -16 413 100 -3 V03AF08 palifermin - - -100 0 - -100 V03AF10 sodium levofolinate 0,00 100 -28 18 100 -55 V03AX Other therapeutic products - - -100 0 - -100 V03AX03 cobicistat - - -100 0 - -100 V04 DIAGNOSTIC AGENTS - - - 897 89 -7 V04C OTHER DIAGNOSTIC AGENTS - - - 897 89 -7 V04CD Tests for pituitary function - - - 108 29 0 V04CD01 metyrapone - - - 108 29 0 V04CF Tuberculosis diagnostics - - - 6 80 -11 V04CF01 tuberculin - - - 6 80 -11 V04CL Tests for allergic diseases - - - 90 81 -39 V04CX Other diagnostic agents - - - 694 100 -1 V04CX05 13C-urea - - - 2 2 -88 V04CX06 hexaminolevulinate - - - 692 100 1 V07 ALL OTHER NON-THERAPEUTIC PRODUCTS - - - 3 076 94 -6 V07A ALL OTHER NON-THERAPEUTIC PRODUCTS - - - 3 076 94 -6 V07AB Solvents and diluting agents, incl. irrigating - - - 3 076 94 -6 solutions Page 68 Drug consumption in current year (Period 202001 - 202012)

Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

V08 CONTRAST MEDIA - - - 21 421 99 0 V08A X-RAY CONTRAST MEDIA, IODINATED - - - 17 065 99 4 V08AA Watersoluble, nephrotropic, high osmolar X-ray - - - 117 100 14 contrast media V08AA01 diatrizoic acid - - - 117 100 14 V08AB Watersoluble, nephrotropic, low osmolar X-ray - - - 16 948 99 4 contrast media V08AB02 iohexol - - - 13 438 100 3 V08AB07 ioversol - - - 2 100 -85 V08AB09 iodixanol - - - 1 060 98 -11 V08AB10 iomeprol - - - 2 448 100 18 V08B X-RAY CONTRAST MEDIA, NON-IODINATED - - - 0 - -100 V08BA Barium sulfate containing X-ray contrast media - - - 0 - -100 V08BA01 barium sulfate with suspending agents - - - 0 - -100 V08C MAGNETIC RESONANCE IMAGING CONTRAST - - - 4 285 98 -15 MEDIA V08CA Paramagnetic contrast media - - - 4 285 98 -15 V08CA02 gadoteric acid - - - 4 049 97 -16 V08CA04 gadoteridol - - - 13 78 -73 V08CA08 gadobenic acid - - - 0 100 10 V08CA09 gadobutrol - - - 16 100 -20 V08CA10 gadoxetic acid - - - 207 100 22 V08D ULTRASOUND CONTRAST MEDIA - - - 70 100 -20 V08DA Ultrasound contrast media - - - 70 100 -20 V08DA01 microspheres of human albumin - - - 2 100 25 V08DA05 sulphur hexafluoride - - - 68 100 -21 V09 DIAGNOSTIC RADIOPHARMACEUTICALS - - - 52 100 -72 V09C RENAL SYSTEM - - - 15 100 -65 V09CA Technetium (99mTc) compounds - - - 15 100 -65 V09CA03 technetium (99mTc) mertiatide - - - 15 100 -65 V09D HEPATIC AND RETICULO ENDOTHELIAL - - - 37 100 -74 SYSTEM V09DB Technetium (99mTc), particles and colloids - - - 37 100 -74 V09DB01 technetium (99mTc) nanocolloid - - - 37 100 -74 Hospital % Sales to hospitals and other health care units as a proportion (%) of the wholesale value Change % is compared with equal period in previous year